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Abstract 
 
Acute urinary retention (AUR) is characterised by the sudden and painful inability 
to pass urine and is common in older men.  It causes significant morbidity, 
frequently results in emergency hospital admission and often requires surgery.  
The aim of this thesis was to investigate ways of improving the management of 
men with AUR. 
 
The Hospital Episode Statistics (HES) database of the Department of Health was 
used to investigate mortality after AUR.  In 100,067 men with spontaneous AUR, 
the one year mortality was 4.1% in men aged 45-54 and 32.8% in those aged 85 
and over.  In men with spontaneous AUR aged 75-84, the most prevalent age 
group, the one year mortality was 12.5% in men without comorbidity and 28.8% 
in men with comorbidity. 
 
The importance of comorbidity on mortality of men with AUR prompted the 
development of The Royal College of Surgeons of England (RCS) Charlson 
Score to improve comorbidity identification in HES.  The RCS Charlson Score 
uses an explicit coding philosophy that is simple to use, more accurate than 
existing adaptations of the Charlson Score, reflects the current understanding of 
the prognostic impact of comorbidity and allows international comparisons. 
 
Given that many men with AUR are elderly, have significant comorbidity and 
therefore have a high risk of death, minimally invasive treatment alternatives to 
surgery for AUR were evaluated.  Systematic literature review defined the role of 
prostatic stents as an effective treatment for frail and elderly men.  Although only 
observational data were available a specifically developed checklist to assess 
methodological quality gave context to the findings. 
 
This thesis demonstrates that the management of AUR must focus not only on 
the prostate but also on the patient’s overall health status.  The urologist should 
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adopt a holistic approach when assessing and treating men with AUR to ensure 
the best possible outcomes.  
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1.1 Introduction and objectives of thesis 
 
This thesis describes work I undertook during a 28 month period as a research 
fellow at the Clinical Effectiveness Unit of the Royal College of Surgeons of 
England.  It is divided into four sections, each sub-divided into chapters 
describing differing aspects of this work. 
 
The overall aim of this thesis was to improve the management of men with acute 
urinary retention (AUR) by studying the epidemiology of AUR and evaluating its 
treatment options.  The specific objectives of this thesis were three-fold.  Firstly, 
to use administrative data from the Hospital Episode Statistics (HES) database 
of the Department of Health to investigate mortality rates after AUR and explore 
the effect of comorbid disease.  Secondly, to develop an updated and improved 
comorbidity score that can be used to explore variations in surgical outcome 
using administrative data such as HES.  Thirdly, to consider the management 
options for men with AUR, especially those who have a high risk of mortality. 
 
Section one is a general introduction and provides the background to the thesis. 
 
Section two considers the epidemiology of AUR.  It includes an overview of our 
current understanding of the aetiology and epidemiology of AUR.  The outcome 
of a man with AUR, in terms of risk of recurrence and the need for surgery, 
depends upon a number of factors including whether or not the retention episode 
occurred either spontaneously or after a precipitating event.  However, the 
prognostic importance of AUR in terms of mortality had not been previously 
investigated.  We hypothesised that AUR might be a marker of underlying 
comorbidity and that men who experience an episode of AUR might have a high 
risk of mortality.  If this hypothesis were true it would have important implications 
regarding the management of AUR and the need to identify and treat 
comorbidity.  Therefore, HES data are analysed to investigate the mortality of 
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men with AUR compared to men in the general population of England without 
AUR and to explore the effects of age and comorbidity. 
 
When using administrative data such as HES for comparative purposes, 
accurate case-mix adjustment is essential, as differences in patient 
characteristics (for example, comorbidity) may contribute to observed variations 
in healthcare outcome.  Therefore, a number of instruments have been 
developed to identify comorbidity in administrative data.  A number of 
disadvantages with the existing comorbidity instruments prompted the 
development of an updated and simplified comorbidity score (The Royal College 
of Surgeons of England (RCS) Charlson Score).  The RCS Charlson Score was 
developed by a consensus group of senior surgeons and epidemiologists having 
first established important general principles for identifying comorbidity in 
administrative data.  The RCS Charlson Score was subsequently validated in 
patients undergoing a range of surgical procedures using HES data. 
 
Section three concentrates on the definitive minimally invasive treatment options 
for men with AUR.  While transurethral resection of the prostate (TURP) is still 
considered the most effective surgical treatment for AUR, it is associated with a 
risk of morbidity and mortality, especially in frail and elderly patients. [Mebust, 
1989; Thorpe, 1994; Brierly, 2001; Nadu, 2004]  Furthermore, TURP may confer 
even greater risk to men who have experienced AUR compared to those who 
have surgery for urinary symptoms alone. [Pickard, 1998]  Therefore, a number 
of minimally invasive treatments have been developed as alternatives to TURP 
and these are considered in this section.  One such treatment is to insert a stent 
(supportive tube) into the prostate of men with AUR thereby relieving obstruction 
and allowing spontaneous voiding once more.  This section specifically evaluates 
the effectiveness, durability and safety of the two commonest types of prostatic 
stent. 
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The principle aim of this thesis was to investigate how the management of men 
with AUR could be improved.  Section four considers the extent to which this 
objective has been addressed by the data and studies presented within this 
thesis.  This thesis raises broader issues regarding the appraisal of minimally 
invasive treatments for AUR and the role of administrative data in the evaluation 
of the quality of healthcare and these are also discussed. 
 
 
1.2 Background to thesis 
 
1.2.1 Epidemiology of acute urinary retention 
Acute urinary retention 
AUR is characterised by the sudden and painful inability to pass urine.  It is 
common in older men, representing a severe and unwanted complication of 
benign prostatic hyperplasia (BPH).  With an ageing population, AUR represents 
a major public health issue in the Western world.  The reported incidence of AUR 
in large population-based studies varies from 2.2 to 6.8 per 1000 men per year. 
[Jacobsen, 1997; Meigs, 1999; Verhamme, 2005; Cathcart, 2006]  In one of 
these studies it was calculated that as many as one in ten men in their seventies 
may experience AUR if they survive for a five-year period. [Jacobsen, 1997] 
 
AUR is a urological emergency that requires immediate treatment by insertion of 
a urinary catheter that allows the bladder to empty.  Most men in the United 
Kingdom are then admitted to hospital although some patients are discharged 
immediately and specialist follow-up is arranged as an outpatient. [Manikandan, 
2004] 
 
Mortality after acute urinary retention 
AUR usually occurs as a result of BPH and as such has often been considered a 
benign condition.  However, AUR usually results in an emergency hospital 
admission and frequently requires surgery.  Moreover, its incidence increases 
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strongly with age and several studies have also found associations with major 
morbidities. [McVary, 2006; Michel, 2004; Ozden, 2007]  We therefore 
hypothesised that AUR may in fact be a seminal event that heralds a poor long-
term prognosis rather than follow an indolent clinical course.  This thesis 
investigates, for the first time, the risk of mortality in men with AUR and explores 
the impact of comorbidity. 
 
The Hospital Episode Statistics database 
The HES database is an administrative database which is funded and managed 
by the Department of Health. [Department of Health, 2000]  Since 1989 records 
of all patients admitted to NHS hospitals in England have been added to the 
database.  Each record includes information on the patient’s demographic 
characteristics as well as details of the admission itself - dates of admission and 
discharge, and details of the patient’s main and supplementary diagnoses and 
operations. 
 
Although initially developed for administrative purposes, the HES database 
provides a rich source of clinical data that can be reliably used to investigate 
important research questions. [Roberts, 2003; Aylin, 2007]  Moreover, the report 
from the inquiry into mortality in a paediatric cardiology department in Bristol 
suggested that ‘the HES database should be supported as a major national 
resource which can be used reliably, with care, to undertake the monitoring of a 
range of healthcare outcomes’. [Bristol Royal Infirmary Inquiry, 2001]  
Consequently, the HES database was chosen to investigate mortality in men 
after AUR through linkage with mortality data from the Office for National 
Statistics. [Office for National Statistics] 
 
Identifying comorbidity 
When considering mortality after AUR, or indeed any other healthcare outcome, 
the presence and severity of comorbid disease are important prognostic factors.  
Several instruments have been developed for identifying comorbidity using 
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administrative data [Elixhauser, 1998; Ghali, 1996; von Korff, 1992] and of these 
adaptations of the Charlson Score are the most widely used and validated. 
[Charlson, 1987; Deyo, 1992; Halfon, 2002; Nuttall, 2006; Quan, 2005; Romano, 
1993; Sundararajan, 2004]  A version of the Charlson Score that has previously 
been validated in patients undergoing urological cancer surgery using HES data 
[Romano, 1993; Nuttall, 2006] was therefore used to identify comorbidity in 
patients with AUR and explore its influence on mortality. 
 
However, a limitation of the Charlson Score, and indeed other comorbidity 
instruments, lies in its poor ability to distinguish conditions that existed prior to 
hospital admission from those that occurred at some point during the admission 
and represent complications of care rather than comorbidities.  Furthermore, the 
Charlson Score was developed in a group of medical patients more than 20 
years ago and the prognostic significance of many of the conditions which it 
describes has now changed considerably.  Therefore, with the specific intention 
of developing an updated and improved version of the Charlson Score for use 
with administrative data, a consensus meeting was convened at the Royal 
College of Surgeons of England.  Chapter 4 is a methodological chapter that 
describes the development and validation of the RCS Charlson Score. 
 
1.2.2 Management of acute urinary retention 
Treatment of acute urinary retention 
After the acute period most men with AUR will be offered a ‘trial without catheter’ 
(TWOC) and about half will resume spontaneous voiding. [McNeill, 2004]  Most 
men who fail a TWOC, experience a recurrent episode of AUR, or have 
moderate or severe lower urinary tract symptoms (LUTS) that are refractory to 
medical management will be considered for surgery. 
 
TURP is still considered the ‘gold standard’ and is used as a reference against 
which other treatment modalities are assessed.  After TURP, urinary symptoms 
are improved and objective increases in urinary flow rates are substantial.  Long-
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term outcomes are favourable with re-operation rates of only 1-2% per year. 
[Madersbacher, 2004]  Technological and anaesthetic advances have 
considerably reduced the morbidity associated with TURP to low but not 
insignificant levels.  A recent review of contemporary TURP series reported a 
very low incidence of perioperative complications (transfusion, 0.4%; TUR 
syndrome, 0%; urinary tract infection, 1.7%; and clot retention, 2%). [Rassweiler, 
2006]  The commonest late complications were urethral stricture (2.2-9.8%) and 
bladder neck stenosis (0.3-9.2%).  Urinary incontinence was very rare (<0.5%).   
 
However, the morbidity and mortality of TURP in frail and elderly patients is 
considerably higher [Mebust, 1989; Thorpe, 1994; Brierly, 2001; Nadu, 2004] 
and in those who have significant comorbidity surgery is not feasible at all.  For 
example, a United Kingdom audit that included men aged over 80 years who had 
a TURP reported an early complication rate of 41% and a late complication rate 
of 22%. [Brierly, 2001]  Another large audit in the United Kingdom found a 
significantly higher post-operative mortality rate after TURP in men with 
comorbidity than in those without.  In men with ASA (American Society of 
Anesthesiologists) scores 3-4 mortality within 90 days of surgery was 8.8% 
(15/170 men) compared to only 2.0% in those with ASA scores 1-2 (10/458 men) 
(p<0.05). [Thorpe, 1994]  Furthermore, men who died within 90 days of TURP 
were significantly older (75 years) than those who survived (71 years) (p<0.001).  
For these reasons minimally invasive treatments have been developed that aim 
to provide comparable effectiveness but lower morbidity than TURP. 
 
The vast majority of these minimally invasive treatments are designed to reduce 
the bulk of the prostate by either ablating or removing the obstructing tissue.  For 
example, transurethral microwave thermotherapy (TUMT) and transurethral 
needle ablation (TUNA) use thermal energy to cause coagulative necrosis and 
hence destruction of prostatic tissue.  Similarly, lasers can be used at low power 
to ablate, or at higher power settings to resect or ‘enucleate’ the prostate.  The 
prostate has been injected with various substances (water, ethanol, botulinum 
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toxin) and prostatic stents (supportive tubes) have been inserted into the 
prostate in an attempt to relieve obstruction.  Unfortunately, the rapidity with 
which many of these technologies have been developed has often precluded 
adequate assessment of their effectiveness, durability and safety.  Most have not 
been subjected to comparison with TURP in randomised controlled trials and 
instead we are often reliant on very limited research evidence of their 
performance.  However, adequate evaluation of these technologies is essential 
so that the clinician can provide patients with accurate information and ensure 
that the most appropriate treatments are offered to them. 
 
Perhaps the most appropriate next step in the evaluation of minimally invasive 
treatment alternatives to TURP is by systematic review.  A systematic literature 
review is a summary of the research evidence that uses explicit methods to 
identify, appraise, select and synthesise relevant studies.  It not only provides 
information on the effectiveness, durability and safety of a treatment but can also 
identify gaps in the evidence base and help to direct future research.  This thesis 
includes two systematic reviews that evaluate the performance of the two 
commonest types of prostatic stent that are used in the treatment of AUR 
(Chapters 6 and 7).  
 
In summary, this thesis for the degree of Doctor of Medicine (Research) aims to 
answer important questions regarding the epidemiology and management of 
AUR.  This programme of work has the potential to improve the quality of care 
offered to the huge number of men who experience AUR - approximately 27,000 
per year in the United Kingdom. [Armitage, 2007; Cathcart, 2006]  It may also 
help to enhance the role of administrative databases such as HES as resources 
for healthcare monitoring and evaluation. 
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1.3 Practical considerations 
 
The Clinical Effectiveness Unit (CEU) of the Royal College of Surgeons of 
England is an academic collaboration between the Health Services Research 
Unit of the London School of Hygiene and Tropical Medicine of the University of 
London and the Royal College of Surgeons of England.  It was established in 
1996 with a remit to study “the epidemiology of the quality of surgical care”.  It 
benefits from a unique combination of clinical and epidemiological expertise and 
since its inception has gained an international reputation as a leader in this field. 
 
In 2005, the Director (Professor Jan van der Meulen) and the Clinical Director 
(Professor Mark Emberton) of the CEU appointed a research fellow (Mr James 
Armitage), who would be responsible for the day-to-day management and 
coordination of a two year research project to investigate the epidemiology and 
management of AUR.  The entire study was funded by the Bob Young Research 
Fellowship, the Dunhill Medical Trust, and the Research Fellowship Scheme of 
the Royal College of Surgeons of England. 
 
The vast majority of the work in this thesis has been undertaken by me.  
However, in the conduct of the research my supervisors, Professor van der 
Meulen and Professor Emberton, and I worked as a team whereby we each 
contributed ideas.  I performed all of the analyses presented here, although 
statistical and methodological guidance was provided by Professor van der 
Meulen.  All literature searches and background research were conducted by 
me, and the entire text has been written by me under the guidance of my two 
supervisors.  This thesis represents original work, although some aspects of the 
work have been based on methods used by other workers, and where this is the 
case appropriate references have been provided. 
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2.1 Objectives 
 
The objectives of this chapter are to describe in brief our current understanding 
of the aetiology and epidemiology of AUR as well as the natural history of BPH 
as background information for readers of this thesis. 
 
 
2.2 Description of the aetiology and epidemiology of acute urinary 
retention 
 
2.2.1 Aetiology of acute urinary retention 
The aetiology of AUR remains poorly understood although a number of factors 
may contribute to its occurrence.  These can be broadly divided into three 
categories. [Choong, 2000]  The first relates to mechanical or dynamic 
obstruction to the normal flow of urine.  This usually occurs in men because 
enlargement of the prostate as a result of BPH causes obstruction of the bladder 
outlet.  Secondly, interruption to the normal sensory innervation of the bladder 
wall or to the motor supply of the detrusor muscle can result in AUR.  The third 
relates to situations where the bladder is allowed to over-distend.  This 
classically occurs after surgery, especially if carried out under general 
anaesthesia, where the risk of AUR is often compounded by post-operative pain, 
an increased adrenergic outflow, and the use of opioid or anticholinergic 
medication. 
 
The precise mechanisms leading to AUR are unclear.  Prostatic infarction, 
increased alpha-adrenergic activity, a low ratio of stromal to epithelial tissue, 
various neurotransmitters, and more recently prostatic inflammation have all 
been implicated. [Spiro, 1974; Choong, 2000; Armitage, 2005]   
 
For example, it is hypothesised that prostatic infarction leads to neurogenic 
disturbance in the peri-urethral zone with a subsequent failure of smooth muscle 
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relaxation.  In a study that analysed the prostatectomy specimens of men who 
had undergone open surgery for either AUR or symptomatic BPH, histological 
evidence of prostatic infarction was present in 85% of the AUR specimens 
compared to just 3% of the BPH specimens. [Spiro, 1974]  However, this 
observation was not supported by a later prospective study that found the rates 
of infarction in TURP specimens did not differ significantly between men who had 
and those who had not experienced AUR. [Anjum, 1998] 
 
Prostatic inflammation has also been proposed as an aetiological factor in the 
occurrence of AUR.  Until recently, most of the evidence to support this 
hypothesis was based on studies that have looked at histological specimens 
obtained after TURP. [Nickel, 1999; Soler, 1999]  However, analysis of the 
outcomes of 1,197 patients enrolled in the Medical Therapy of Prostatic 
Symptoms (MTOPS) study who had transrectal prostate biopsy provides further 
evidence for the role of prostatic inflammation. [Roehrborn, 2005; McConnell, 
2003]  Overall, during the 4.5 years follow-up, patients with prostatic 
inflammation were significantly more likely to develop AUR than those without 
(2.4 vs. 0.6%, p=0.011). The finding that challenges current views on the 
pathogenesis of progression were in the placebo group, in which, in the 
presence of inflammation, 5.6% went on to develop AUR compared to none of 
the patients with no prostatic inflammation.  
 
Benign prostatic hyperplasia 
BPH is the commonest benign neoplasm in men and a major aetiological factor 
in the occurrence of AUR.  The term BPH is, however, the source of 
considerable confusion.  It is a histological diagnosis characterised by the 
presence of varying degrees of stromal and epithelial hyperplasia.  Its 
prevalence increases with age such that approximately 60% of men in their fifties 
and 90% of men in their eighties have evidence of the disease. [Berry, 1984] 
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Hyperplasia of both stromal and epithelial elements of the prostate is thought to 
result from abnormal cellular proliferation and glandular apoptosis. [Zhang, 2006]  
Androgens are believed to play a permissive role, a fact supported by the 
observation that boys castrated before puberty do not develop BPH. [White, 
1895]  Dihydroxytestosterone is synthesised from testosterone predominantly by 
the stromal cells where it exerts autocrine and paracrine effects.  It binds to 
androgen receptors in stromal and epithelial cells and signals the transcription of 
growth factors that are mitogenic to both of these cell types. 
 
BPH may be evident anatomically as benign prostatic enlargement.  Also, the 
relatively inflexible prostate capsule means that cellular proliferation in the peri-
urethral and transitional zones can lead to compression of the urethra and 
therefore bladder outflow obstruction.  This may result in the clinical 
manifestations of the disease such as lower urinary tract symptoms (LUTS) and 
AUR. 
 
2.2.2 Incidence of acute urinary retention 
Recent community-based studies have provided some insight into the incidence 
of AUR both in the general population and in men who have sought medical 
advice who are presumed to have BPH. 
 
Incidence of acute urinary retention in the general population 
A recent study based on the HES database estimated an incidence of AUR in 
England of 3.1/1000 men per year. [Cathcart, 2006]  A Dutch epidemiological 
study, the only population-based study to date in which the incidence of AUR 
was estimated through direct access to a prospectively collected primary care 
database, reported a slightly lower incidence of 2.2/1000 men per year (95% 
confidence interval (CI), 2.0-2.4). [Verhamme, 2005]  Two large community-
based studies provided estimates of the incidence of AUR in the United States.  
The Olmsted County Study followed 2,115 community-dwelling men for a total of 
8,344 person years. [Jacobsen, 1997]  The overall incidence of AUR was 
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6.8/1000 men per year (95% CI, 5.2 to 8.9).  During 15,851 person years of 
follow-up, the Health Professionals Study reported an incidence of 4.5/1000 men 
per year (95% CI, 3.1 to 6.2). [Meigs, 1999] 
 
Incidence figures for AUR in community dwelling men therefore range 
considerably from 2.2/1000 men per year to 6.8/1000 men per year.  The lowest 
incidence figure (2.2/1000 men per year) reported in the Dutch study may be 
explained by their strict case definition which required evidence both of a sudden 
inability to pass urine and of catheterisation.  The higher incidences reported in 
the American studies may be explained by selection bias as these studies 
included only men who had responded to a detailed questionnaire.  In other 
words, men with more bothersome urinary symptoms, and therefore a greater 
risk of developing AUR, [Jacobsen, 1997; Meigs, 1999; Roehrborn, 1999] are 
more likely to have completed a questionnaire enquiring about severity of LUTS. 
 
Incidence of acute urinary retention in men with BPH 
The incidence of AUR in men with clinically diagnosed BPH has been found to 
be appreciably higher than in men in the general population who have not sought 
a medical opinion for LUTS suggestive of BPH. [Barry, 1997; McConnell, 1998; 
McConnell, 2003; Verhamme, 2005] 
 
A cohort of 500 men with clinical BPH who were candidates for prostatectomy 
but elected to be treated non-operatively were followed-up for four years 
although only 371 were evaluable at the end of the study period. [Barry, 1997]  
Forty men experienced AUR in 1,574 person-years of follow-up to give an 
incidence figure of 25/1000 men per year.  The Dutch database study also 
evaluated the incidence of AUR in men with newly diagnosed LUTS or BPH. 
[Verhamme, 2005]  The incidence of AUR in this cohort was 18.3/1000 men per 
year (95% CI, 14.5-22.8), considerably higher than the overall incidence of 
2.2/1000 men per year. 
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The placebo arms of the Proscar Long-term Efficacy and Safety Study (PLESS) 
and MTOPS trial also provide excellent opportunities to observe the natural 
history of clinically diagnosed BPH. [McConnell, 1998; McConnell, 2003]  In 
PLESS, men were randomised to receive either finasteride (a 5-alpha reductase 
inhibitor) or placebo.  In 1,376 placebo-treated men with enlarged prostates and 
moderate LUTS the incidence of AUR was 18/1000 men per year.  In the 
placebo arm of the MTOPS study, the overall incidence of AUR was 2%, or 
6/1000 men per year.  However, the low figure reported in the MTOPS study is 
likely to be an underestimate of the true incidence of AUR for the following 
reasons.  First, men who experienced other markers of BPH disease progression 
(worsening of International Prostate Symptom Score by ≥4 points, recurrent 
urinary tract infections, renal insufficiency, or incontinence) were censored and 
AUR, if it subsequently occurred, was not recorded.  Second, the MTOPS trial 
excluded all men with precipitated AUR (urinary retention after a triggering event, 
see later) unless a TWOC was unsuccessful. 
 
2.2.3 Risk factors for acute urinary retention 
Several risk factors for the development of AUR have been identified.  The 
Health Professionals Followup Study found that both age and baseline symptom 
severity increased the risk of AUR. [Meigs, 1999]  In men with mild symptoms 
the incidence increased from 0.4/1000 men per year in men aged 45 to 49 years 
to 7.9/1000 men per year in those aged 70 to 83 years.  In men with moderate or 
severe symptoms the incidence rates increased from 3.3/1000 men per year to 
11.3/1000 men per year for the youngest and oldest age-groups respectively.  
Furthermore, each of the seven domains comprising the International Prostate 
Symptom Score (IPSS) was found to predict AUR.  A sensation of incomplete 
voiding, urinary frequency and a poor urinary stream had the strongest predictive 
values. 
 
Age, symptom severity, prostate volume, and urine flow rates were identified as 
independent risk factors for the occurrence of AUR in the Olmsted County Study. 
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[Jacobsen, 1997]  The incidence of AUR increased from 2.6 to 9.3/1000 men per 
year for men in their forties to seventies if they had mild symptoms, and from 3.0 
to 34.7/1000 men per year if they had moderate or severe symptoms.  The 
relative risk (RR) of AUR increased for men with moderate or severe symptoms 
(RR 3.2), those with flow rates of less than 12ml/s (RR 3.9), and those with 
prostate volumes of greater than 30ml (RR 3.0), all compared to a baseline risk 
of 1.0 for the corresponding groups. 
 
Data from the placebo arm of the PLESS study demonstrated that prostate 
volume, PSA and symptom severity were all predictors of AUR occurrence. 
[Roehrborn, 1999]  In men with a serum PSA of less than 1.4ng/ml, the incidence 
of AUR increased from 5.6% for those with mild symptoms to 7.7% for those with 
severe symptoms, and in men with a PSA of more than 1.4ng/ml the respective 
incidences were 7.8% and 10.2%. 
 
A pooled analysis of data from the placebo-treatment arms of PLESS 
[McConnell, 1998] and three other prospective randomised controlled trials each 
with 2 years follow-up [Anderson, 1995; Nickel, 1998; Marberger, 1998] was 
undertaken by Roehrborn. [Roehrborn, 2001]  Serum PSA and prostate volume 
were found to be strong predictors of AUR.  Interestingly, from more than 110 
variables that were assessed, the logistic models with PSA alone performed 
almost as well as expanded models that included PSA, urinary frequency and 
hesitancy, flow rate parameters and urinary symptoms. 
 
An individual’s response to treatment has recently been identified as a predictor 
of the risk of BPH disease progression and AUR. [Armitage, 2005]  In the Health 
Professionals Followup Study, the incidence of AUR was higher in patients 
whose overall or individual LUTS had worsened over a two-year period 
independent of baseline severity. [Meigs, 1999]  This observation was supported 
by data from the Alf-One study in which 3,514 patients with LUTS were treated 
with the alpha-receptor blocker alfuzosin 10mg daily. [Emberton, 2005]  A prior 
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episode of AUR was found to be the most important predictor of AUR (Hazard 
Ratio 6.35, 95% CI 2.31 to 17.40; p<0.01).  However, the next strongest 
predictors of AUR were IPSS worsening of 4 or more points (HR 3.34, 95% CI 
1.11 to 9.99; p=0.03) and a bother score greater than 3 at endpoint (HR 3.32, 
95% CI 1.29 to 8.53; p<0.01).  Deteriorating urinary symptoms were similarly 
associated with an increased risk of BPH surgery. 
 
 
2.2.4 Spontaneous and precipitated acute urinary retention 
AUR may be classified as occurring either spontaneously or after a triggering 
event. [Jacobsen, 1997; Roehrborn, 2000]  Retention episodes preceded by 
surgery, anaesthesia, or ingestion of medications such as alpha-
sympathomimetics, over-the-counter cold medications, antihistamines or 
anticholinergics may be classified as precipitated AUR.  All other episodes of 
retention not preceded by a triggering stimulus may be considered to be 
spontaneous AUR.  This is an important distinction as patients with spontaneous 
and precipitated AUR are likely to have different outcomes. 
 
For example, almost half of the men who experienced AUR in the Olmsted 
County study were identified as having undergone a surgical procedure prior to 
retention, 90% of whom had had a general anaesthetic. [Jacobsen, 1997]  Of 
these men with precipitated AUR, only 14% (eight patients) subsequently 
required surgery and only one patient experienced a further episode of retention 
within the four year study period. 
 
In the PLESS study, of 1,503 placebo-treated patients, 99 experienced one or 
more episodes of AUR over the four-year follow-up period. [Roehrborn, 2000]  
Approximately equal proportions had spontaneous and precipitated AUR.  Of the 
52 patients who had spontaneous AUR, nine (17%) experienced a recurrent 
episode of retention.  The recurrence rate after precipitated AUR was similar – 
10 out of 47 patients (21%).  However, a significantly greater proportion of 
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patients with spontaneous AUR went on to receive surgical intervention (75%) 
compared to those with precipitated AUR (26%). 
 
Of the 344 patients who experienced AUR in the Dutch epidemiological study 
[Verhamme, 2005], more than 40% were considered to have had precipitated 
retention.  AUR was preceded by a procedure (surgery, urological interventions, 
anaesthesia) in 77 cases (22%) and a further 72 cases (21%) were preceded by 
a urinary tract infection, the presence of a neurological disorder, or treatment 
with a drug that has been associated with AUR 
 
2.2.5 Outcome of acute urinary retention 
AUR is initially treated by inserting a urinary catheter.  The catheter is usually 
introduced urethrally, although some urologists favour a suprapubic approach. 
[Desgrandchamps, 2006; Manikandan, 2004]  The suprapubic procedure is more 
complex and requires an additional level of training that is usually only attained 
by urologists.  Suprapubic catheterisation is associated with different morbidity 
compared to the urethral approach with bowel perforation the most feared 
complication.  An audit of more than 200 patients who had a suprapubic catheter 
inserted under cystoscopic guidance (not for AUR) reported an overall 
complication rate of 29% within 30 days including a 2.4% incidence of bowel 
perforation. [Ahluwalia, 2006]  Mortality in this series was 1.8%.  Recent 
innovation in suprapubic catheter design, for example the Mediplus catheter 
which employs the Seldinger technique, aims to reduce the morbidity of the 
procedure.  
 
However, for men with AUR who have not had previous abdominal surgery and 
where there is appropriate surgical expertise available, a suprapubic catheter 
may confer a number of advantages over a urethral catheter.  For example, it 
may be associated with a lower incidence of urinary tract infection, [Horgan, 
1992] and may be less uncomfortable, easier for the patient to manage, and 
more cost-effective than a urethral catheter. [Ichsan, 1987]  What is more, a 
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suprapubic catheter can be clamped to assess whether or not a man can resume 
spontaneous voiding, negating the discomfort of removal and the trauma of 
catheter reinsertion if the patient is unable to pass urine. 
 
Clean intermittent self-catheterisation after a short period of indwelling 
catheterisation has been advocated by some urologists. [Patel, 2001]  
Intermittent catheterisation has several advantages over an indwelling catheter.  
It allows a patient to restore normal bladder ‘cycling’, permits sexual activity, and 
reduces the incidence of bacterial colonisation of the urinary tract. 
 
Trial without catheter 
AUR on a background of LUTS attributable to BPH was once considered an 
absolute indication for surgery.  Today, most men who experience AUR are first 
considered for a TWOC to determine whether or not they are able to resume 
spontaneous voiding. [Desgrandchamps, 2006; Manikandan, 2004]  Men who 
are unable to pass urine when the catheter is removed are usually considered for 
TURP. 
 
The administration of an alpha-receptor blocker has been shown to increase the 
chance of a successful TWOC.  A recent randomised controlled trial reported a 
successful TWOC in 61.9% of men who were given a minimum of two doses of 
alfuzosin 10mg once daily prior to catheter removal compared to 47.9% who 
received placebo. [McNeill, 2004]  Elderly patients (over 65 years) and those with 
residual urine volumes of more than one litre were less likely to have a 
successful TWOC but administration of alfuzosin almost doubled the likelihood of 
success. 
 
A related study that reported longer follow-up (mean 7.2 months) of patients who 
had undergone a successful TWOC found that most (68%) required no further 
intervention. [McNeill, 1999]  The other 32% experienced recurrent AUR or went 
on to have a TURP.  Increased post-void residual urine after TWOC was found 
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to predict recurrent AUR and the need for surgery but no other prognostic 
factors, for example age or residual urine volume, were identified. 
 
A successful TWOC and resumption of spontaneous voiding is desirable for a 
number of reasons.  First, the morbidity and inconvenience associated with 
indwelling catheters is well documented. [Kohler-Ockmore, 1996]  Second, 
catheter removal permits a thorough evaluation of a patient’s symptoms and 
careful consideration of the merits of surgical intervention.  Third, the absence of 
a catheter may reduce the incidence of sepsis if surgical intervention is required. 
[Hargreave, 1982; Cravens, 2000]  Fourth, the morbidity and mortality associated 
with prostatectomy after AUR may be greater than that of surgery for urinary 
symptoms alone. [Mebust, 1989; Pickard, 1998] 
 
It is not always straightforward to predict which patients will successfully void 
after catheter removal following AUR.  Furthermore, consensus has not been 
reached on the optimal duration of catheterisation prior to TWOC.  A recent 
study randomised 114 men presenting with AUR to one of three groups: ‘in-and-
out’ catheterisation or TWOC at two days or seven days after catheter insertion. 
[Djavan, 1998]  TWOC was successful in 44%, 51% and 62% of patients in the 
respective groups, suggesting that the success of TWOC increased with longer 
periods of catheterisation.  This study also found that men aged less than 75 
years, with retention volumes of less than 1000ml, and detrusor pressures at 
peak flow of greater than 35cmH20 had better chances of successful voiding 
independent of duration of catheterisation.  Patients with retention volumes of 
more than 1300ml had better outcomes with longer periods of catheterisation 
before TWOC. 
 
Long-term outcome of acute urinary retention (recurrence and surgery) 
The introduction of medical treatments for BPH, specifically alpha-receptor 
blockers and 5-alpha reductase inhibitors, in the Nineteen Nineties has 
revolutionised the management of LUTS and AUR.  Both alpha-receptor blockers 
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and 5-alpha reductase inhibitors have been shown to improve urinary symptoms 
associated with BPH.  Moreover, 5-alpha reductase inhibitors have also been 
shown to substantially reduce the risk of AUR. [Roehrborn, 2000; McConnell, 
2003]  Furthermore, there is good evidence that the number of TURPs being 
performed both in the United Kingdom and in the United States is falling and that 
this corresponds to the increased use of BPH drug treatments. [Cathcart, 2006; 
Logie, 2005; Wasson, 2000]  
 
Prior to the regular use of BPH drug treatments, a prospective study of 228 men 
presenting with AUR found that 56% experienced recurrent retention within 1 
week and 68% had recurrence within 1 year. [Klarskov, 1987]  Factors that 
predicted AUR recurrence in this study were retention volumes of greater than 
500ml, maximum urine flow rates of less than 5ml/s after catheter removal, and 
the absence of a precipitating event. 
 
In the placebo arm of men recruited to the PLESS trial, 99 men experienced 
AUR. [Roehrborn, 2000]  Of the 52 men who had spontaneous retention, 17% 
experienced recurrent AUR compared to 21% of the 47 men with precipitated 
AUR.  However, 39 men (75%) with spontaneous AUR subsequently required 
surgery compared to just 12 (26%) of those with precipitated retention.  For men 
treated with a 5-alpha reductase inhibitor (finasteride), four (20%) with 
spontaneous AUR and three (14%) with precipitated AUR experienced recurrent 
retention.  There was a significant between-group difference in the incidence of 
surgery following spontaneous AUR - only eight of the 20 (40%) finasteride-
treated patients who experienced spontaneous AUR required surgery compared 
to 39 of the 52 (75%) placebo-treated patients. 
 
Recurrence after AUR was estimated in an English population through analysis 
of HES data. [Cathcart, 2006]  Rates of recurrence within six months after AUR 
were higher after spontaneous (20%) than after precipitated (5%) retention.  
Similarly, the proportion of patients requiring surgery within six months after AUR 
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was higher after spontaneous retention (about 30%) than after precipitated AUR 
(about 6%). 
 
2.2.6 Summary 
Although the precise aetiology of AUR remains unclear, it often occurs in men as 
a complication of BPH.  Several risk factors for AUR have been identified 
including patient age.  Therefore, with an ageing population the high incidence of 
AUR in the Western world is likely to increase further still and represent a major 
public health issue. 
 
The management of AUR has changed considerably since the introduction of 
medical therapy that has been shown to reduce the risk of developing AUR and 
to improve the chance of resuming spontaneous voiding in those men who do 
experience AUR.  Effective medical therapy has therefore resulted in a decline in 
the number of TURPs that are now performed.  The studies presented here also 
highlight an important differentiation between AUR that occurs spontaneously 
from that which occurs after a precipitating event.  Patients with precipitated AUR 
are less likely to experience recurrent AUR or go on to require surgery.  A 
distinction between spontaneous and precipitated AUR becomes apparent once 
more when mortality is investigated in Chapter 3. 
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Chapter 3 
 
 
Exploring the hypothesis that acute urinary retention confers a 
high risk of mortality 
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3.1 Objectives 
 
This chapter investigates the hypothesis that AUR may be a ‘harbinger’ of severe 
systemic disease and therefore predicts a poor long-term prognosis.  We use 
administrative data from the Hospital Episode Statistics (HES) database of the 
Department of Health to investigate mortality rates after AUR and explore the 
effect of comorbid disease. 
 
 
3.2 Methods 
 
3.2.1 Data 
We extracted data from the HES database, an administrative database of all 
admissions to National Health Service hospitals in England. [Department of 
Health, 2007]  Admissions between 1st April 1998 and 31st March 2005 were 
included.  A unique patient identifier allowed us to link records of different 
hospital admissions of the same patient.  Each HES record contains diagnostic 
fields coded according to the International Classification of Diseases (ICD-10) 
[World Health Organisation, 1994] and operative procedure fields coded 
according to the UK Tabular List of the Classification of Surgical Operations and 
Procedures. [Office of Populations Censuses and Surveys, 1996]  For all 
admissions after 1st April 1998, the HES database was linked to the mortality 
database of the Office for National Statistics. [National Centre for Health 
Outcomes Development]  In 2.4% of men who were reported as having died after 
AUR, a record of a subsequent hospital admission was found.  For these 
contradictory results, the information on death was considered to be erroneous 
and these men were therefore analysed as being alive until the end of the study 
period. 
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3.2.2 Definitions 
A patient was considered to have had primary AUR (AUR for the first time), if 
there was no record in the HES database of a previous admission for AUR in at 
least the preceding 6 months.  A period of 6 months was chosen because about 
80% of men who experience recurrence do so within this time period. [Cathcart, 
2006] 
 
Furthermore, AUR was defined as spontaneous if AUR (R33) was recorded in 
the first diagnostic field, or if BPH (N40) was the primary diagnosis and AUR was 
recorded in another diagnostic field.  All other cases of AUR were considered 
precipitated. [Cathcart, 2006; McNeill, 2004; Roehrborn, 2000] 
 
3.2.3 Inclusion criteria 
To identify admissions of men aged over 45 years who had primary AUR, we 
followed a step-wise process.  First, we selected the records of all 229,089 men 
who were admitted at least once with an ICD-10 code indicating AUR (R33) in 
any of the first seven diagnostic fields between 1st April 1998 and 31st March 
2005.  Second, we sequentially deleted the records of 29,924 patients with an 
ICD-10 code indicating prostate cancer (C61), of 1,150 patients with a code 
indicating multiple sclerosis (G35), and of 6,380 patients with a code indicating 
Parkinson’s disease (G20) in any diagnostic field of any record.   Third, we 
excluded the records of 15,592 men who were admitted for AUR in the period 
between 1st April 1998 and 30th September 1998 in order to include only men 
with primary AUR. 
 
3.2.4 Identification of comorbidity 
We used an adaptation of the Charlson Score designed for use with 
administrative data. [Charlson, 1987; Romano, 1993]  This score was validated 
in HES data for patients undergoing urological cancer surgery in England. 
[Nuttall, 2006]  Comorbid disease was defined as present if it appeared in the 
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records of the index admission (the admission for primary AUR) or of hospital 
admissions that occurred in the 6 months preceding AUR. 
 
3.2.5 Statistical analysis 
The Kaplan-Meier method was used to estimate age-specific mortality within 90 
days and 1 year after primary AUR.  To compare mortality within the first year 
after AUR to that of men in the general population, standardised mortality ratios 
(SMRs) were calculated according to age and comorbidity.  Age-group and 
calendar year-specific mortality rates of men in the general population of 
England in the years 1999 to 2005 were used as standard rates.  The 
standardised rates were calculated by dividing the mid-year estimate of the 
number of men within an age-group alive in England and Wales by the number 
that died during that year.  The confidence intervals for the SMRs were obtained 
using Byar’s approximation. [Breslow, 1987] 
 
 
3.3 Results 
 
Between 1st October 1998 and 31st March 2005, 176,046 men were admitted to 
NHS hospitals with a diagnosis of primary AUR (Table 3.1).  Of these men, 
100,067 (56.8%) had spontaneous AUR and their mean age was 73.5 (SD 10.5) 
years.  75,979 men (43.2%) had precipitated retention and their mean age was 
74.5 (SD 10.9) years.  In all age-groups, men with precipitated AUR had a higher 
mortality than men with spontaneous AUR. 
 
Overall, 14.7% of men with spontaneous AUR and 25.3% of men with 
precipitated AUR died within the first year (Table 3.1).  Roughly half of these 
deaths (54.9%) occurred within the first 90 days. 
 
In men with spontaneous AUR, 1-year mortality increased strongly with age from 
4.1% in patients aged between 45 and 54, to 32.8% in those aged over 85 years 
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(Table 3.1).  In men with precipitated AUR, 1-year mortality increased to a similar 
extent in the corresponding age-groups from 9.5% to 45.4%. 
 
Although the highest 1-year mortality was observed in the oldest age-groups, the 
age-specific relative increase in mortality was highest in the youngest age-
groups (Table 3.1).  In men aged between 45 and 54 years with spontaneous 
AUR, there was a 10-fold increase and in men with precipitated AUR an almost 
24-fold increase in mortality compared to the general population.  In men aged 
over 85 years with spontaneous AUR, there was a 1.7-fold increase and in men 
with precipitated AUR a 2.4-fold increase. 
 
More than one third of men with AUR were found to have at least one major 
comorbid condition as defined by the Charlson Score (Table 3.2).  As expected, 
comorbidity was more prevalent in men with precipitated AUR (43.5%) than in 
men with spontaneous AUR (29.1%).  The presence of comorbidity greatly 
increased mortality.  For example, in men with spontaneous AUR aged between 
75 and 84 years, the most frequent age-group, the presence of comorbidity more 
than doubled the 1-year mortality from 12.5% to 28.8%.  In men with precipitated 
AUR in the corresponding age-group, the presence of comorbidity had a similar 
effect, and 1-year mortality increased from 18.1% to 40.5%. 
 
Very high 1-year mortalities were observed in men with comorbidity in the oldest 
age-group (44.3% in men with spontaneous AUR and 54.7% in men with 
precipitated AUR).  However, the age-specific relative increase compared to the 
general population is again highest in the youngest age-group (SMR of 36.5 in 
men with spontaneous AUR and 60.4 in men with precipitated AUR). 
 
Even in men without comorbidity as defined by the Charlson Score, mortality 
within the first year after AUR was considerably higher than in the general 
population (Table 3.2).  For example, in men with spontaneous AUR without 
comorbidity mortality was 4.4 times higher than in the general population in the 
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youngest age-group and 1.4 times higher in the oldest age-group.  Similarly, in 
men with precipitated AUR without comorbidity, mortality was 8.4 times higher in 
the youngest age-group and 2.0 times higher in the oldest age-group. 
 
 
3.4 Discussion 
 
Mortality after primary AUR in men admitted to hospital is very high.  Overall, we 
found that one in seven men with spontaneous AUR and one in four with 
precipitated AUR died in the first year.  Mortality rates increased strongly with 
age and the presence of comorbidity.  Consequently, about half of the men aged 
over 85 years with at least one comorbid condition died within the first year after 
AUR.  Although mortality in men younger than 55 years without comorbidity is 
not as high, it was still at least 4 times higher than that observed in men of 
similar age in the general population. 
 
3.4.1 Methodological limitations 
We report the mortality of men with AUR who were admitted to hospital.  Men 
who were treated within a primary care setting and those who were treated solely 
in a hospital emergency department were not considered.  Those patients may 
have been in a better overall condition than the patients who were admitted.  
However, according to a recent survey, only 10% of UK urologists would not 
admit men who present with AUR to hospital. [Manikandan, 2004]   Also, a 
recent Dutch epidemiological study, the only population-based study to date in 
which the incidence of AUR was estimated through direct access to a 
prospectively collected primary care database, reported an incidence of 2.2 per 
1000 men per year. [Verhamme, 2005]  This is lower than the AUR incidence of 
3.1 per 1000 men per year that we reported previously based on hospital 
admissions in England. [Cathcart, 2006]  It is therefore unlikely that our study 
missed a substantial number of men with AUR. 
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The Charlson Score based on administrative data underestimates the 
prevalence of comorbid disease. [Romano, 1993a; Schneeweiss, 2000]  
Undetected comorbidity may account for our observation that AUR patients 
without comorbidity according to the Charlson Score still had a higher mortality 
than the general population.  Nonetheless, we found that the Charlson Score 
identified at least one comorbid condition in more than a third of men with AUR 
and that mortality was most increased in this group.  A more accurate instrument 
would have demonstrated an even more marked impact of comorbidity. 
 
The mortality after AUR reported in this study is based on the linkage between 
the HES database of all admissions to NHS hospitals in England and the 
mortality database of the Office for National Statistics.  96% of patients had a 
date of death that was based on very robust linkage methods that relied on an 
exact match of at least two of the following three domains: NHS number (a 
unique 10 digit code allocated to an individual to enable identification for NHS 
healthcare), date of birth, and postcode.  For these patients, we found 
contradictory linkage results (i.e. an admission date after a date of death) in only 
0.3% of patients.  In the remaining 4% of patients, a less robust linkage method 
(partial match of date of birth, and exact agreement of sex and postcode) was 
used and contradictory results were found in 54% of the patients.  As explained 
before, men with contradictory mortality results were analysed as being alive 
until the end of the study period.  Sensitivity analyses found that the mortality for 
all men within 1 year after AUR changed by less than 0.5 percent point, and in 
turn the relative increases in mortality compared to the general population did not 
change appreciably. 
 
3.4.2 Comparison with other studies 
This is the first study that specifically reports longer-term mortality after AUR.  
The only study to date that provides some evidence on mortality after AUR was 
carried out in 5 healthcare regions in the UK in the mid Nineties in 3,966 men 
who underwent prostatic surgery. [Pickard, 1998]  This study demonstrated that 
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the 1,242 men who underwent a prostatectomy after AUR had a higher mortality 
in the first 90 days (3.0%) than the 2,724 men who had surgery for symptoms 
alone (0.7%).  Other studies that report on outcomes after AUR tend to focus 
only on recurrence and the need for prostatic surgery. [Roehrborn, 2000; 
Cathcart, 2006] 
 
AUR shares a number of characteristics with fractured neck of femur.  Both are 
acute and serious age-related events that almost always result in hospital 
admission.  Also, AUR like fractured neck of femur does not directly cause death.  
Two English studies have recently reported the 1-year mortality in men after 
fractured neck of femur to be just over 40%. [Roberts, 2003; Roche, 2005]  The 
mortality clearly increased with age from 20% in men aged between 65 and 69 
years to 50% in men aged between 85 and 89. [Roberts, 2003]  Also for 
fractured neck of femur, comorbidity was found to be an important predictor of 
outcome.  Mortality in the first year after fractured neck of femur was about 1.5 
times higher in patients with at least one comorbid condition than in patients 
without comorbidity. [Roche, 2005]  
 
The comparison with fractured neck of femur demonstrates that AUR constitutes 
a health problem of a similar magnitude.  The overall 1-year mortality after AUR 
is 20% which is lower than that observed after fractured neck of femur.  
However, the incidence of primary AUR is 3.1 per 1000 men per year which is 
higher than the incidence of fractured neck of femur that can be estimated to be 
about 2.4 per 1000 men per year based on HES data. [Department of Health, 
2007] 
 
3.4.3 Explanations for the increased mortality 
AUR is generally considered a urological emergency that if appropriately treated 
rarely has serious consequences.  Our finding of a high mortality in the first year 
after AUR seems to contradict this.  An obvious explanation for the increased 
mortality is that the occurrence of AUR exposes men to risks associated with 
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hospitalisation, catheter-related and other nosocomial infections as well as to 
invasive procedures that often need a general anaesthetic. 
 
While these factors do play a role, the high mortality seems to be linked mainly to 
comorbidity for a number of reasons.  First, the presence of comorbidity 
according to the Charlson Score substantially increased mortality within patients 
of similar age and with the same type of AUR.  Second, mortality was also higher 
in patients with precipitated AUR than with spontaneous AUR.  Per definition, 
precipitated AUR occurs after a triggering event that is unrelated to the prostate 
and therefore a further indication of comorbidity.  Third, there appears to be a 
‘dose - response’ relationship as the lowest mortality was found in patients with 
spontaneous AUR and no comorbidity according to the Charlson Score and the 
highest mortality in patients with precipitated AUR and comorbidity.  Last, a 
detailed inspection of the diagnostic fields in patients with spontaneous AUR and 
apparently no comorbidity reveals that 58% of these patients had at least one 
non-prostate-related diagnosis not captured by the Charlson Score. 
Of the patients who had comorbidity according to the Charlson Score, 
irrespective of the type of AUR, about 30% had cardiovascular disease, 25% 
diabetes, 25% chronic pulmonary disease, and 15% a malignancy.  The 
relatively high prevalence of cardiovascular disease and diabetes is consistent 
with the findings of recent aetiological studies linking hypertension and metabolic 
syndrome with the progression of BPH. [Michel, 2004; Ozden, 2007] 
 
3.4.4 Clinical implications 
The high mortality that we observed in hospitalised men with AUR demonstrates 
that they are a vulnerable group of patients.  These observations reinforce the 
importance to the clinician of adopting a multi-disciplinary approach when 
assessing and managing men with AUR. [Kirby, 2005]  Men who experience 
AUR should undergo a comprehensive assessment for the presence of comorbid 
disease and where it is identified it should be treated appropriately.  However, 
the extent to which mortality after AUR can be reduced will depend on the nature 
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and severity of the comorbidities involved and the effectiveness of the available 
treatments.  For example, some patients will have comorbidity that is already 
optimally treated and for whom little further can be done. 
 
Our observation that about half of the deaths after AUR occur within the first 90 
days suggests that comorbidity assessment must occur promptly.  Taking the 
need to be timely one step further, one could claim that to be most effective 
screening for other morbidities should start in men presenting with LUTS 
attributable to BPH before these patients have experienced AUR. 
 
3.4.5 Research implications 
The two most important unanswered questions relate to the way in which 
comorbidities can be identified and the extent to which their treatment will reduce 
mortality after AUR.  In our view, research building on administrative databases, 
such as the HES database, enriched through linkage with additional clinical data 
seems to be the obvious next step to answer both questions.  First, 
administrative databases can provide near complete follow-up in terms of further 
treatment as well as death.  Clinical data, perhaps collected prospectively in a 
subgroup of patients and linked to the administrative data at individual patient 
level, will allow a further exploration of the impact of comorbidity according to its 
nature and severity.  It can be envisaged that the results of this step will inform 
the development of treatment strategies.  Second, these strategies can then be 
evaluated using research designs that build on combining administrative data 
with data derived from clinical trials. 
 
 
 
3.5 Tables 
 
Table 3.1: Age-specific mortality within 90 days and 1 year after spontaneous and precipitated primary AUR and standardised mortality 
ratios (SMR) against the general population of England 
 
   Mortality 
 Total  90 days  1 year   
Age-group Admissions  Deaths Rate % (95% CI)  Deaths Rate % (95% CI)  SMR (95% CI) 
Spontaneous AUR  
 
        
45-54 5,580  119 2.2 (1.8-2.6)  216 4.1 (3.6-4.6)  10.0 (8.8-11.5) 
55-64 13,918  329 2.4 (2.2-2.7)  692 5.3 (4.9-5.7)  5.0 (4.6-5.4) 
65-74 30,661  1,301 4.3 (4.1-4.5)  2,822 9.7 (9.4-10.1)  3.3 (3.2-3.4) 
75-84 36,086  2,752 7.8 (7.5-8.0)  6,070 17.9 (17.4-18.3)  2.3 (2.2-2.3) 
>85 13,822  2,153 15.8 (15.2-16.4)  4,315 32.8 (32.0-33.7)  1.7 (1.6-1.7) 
Total 100,067  6,654 6.7 (6.5-6.8)  14,115 14.7 (14.5-14.9)  2.2 (2.2-2.3) 
Precipitated AUR          
45-54 4,979  276 5.6 (5.0-6.3)  453 9.5 (8.7-10.4)  23.6 (21.5-25.9) 
55-64 8,736  625 7.2 (6.7-7.8)  1,043 12.5 (11.8-13.2)  12.0 (11.3-12.8) 
65-74 20,461  2,095 10.3 (9.9-10.8)  3,492 17.8 (17.3-18.3)  6.1 (5.9-6.3) 
75-84 28,148  4,551 16.4 (15.9-16.8)  7,711 28.7 (28.1-29.2)  3.7 (3.6-3.8) 
>85 13,655  3,792 28.0 (27.3-28.8)  5,983 45.4 (44.6-46.3)  2.4 (2.3-2.4) 
Total 75,979  11,339 14.8 (14.6-15.1)  18,682 25.3 (24.9-26.3)  3.5 (3.5-3.6) 
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Table 3.2: Age-specific mortality within 1 year after spontaneous and precipitated primary AUR and standardised mortality ratios (SMR) 
with and without comorbidity 
 
 Men without comorbidity (Charlson Score=0)  Men with comorbidity (Charlson Score≥1) 
 Total  1 year  Total  1 year 
Age-group Admissions  Deaths Rate % (95% CI) SMR (95% CI)  Admissions  Deaths Rate % (95% CI) SMR (95% CI) 
Spontaneous AUR            
45-54 4,590  77 1.8 (1.4-2.2) 4.4 (3.4-5.4)  990  139 14.7 (12.6-17.2) 36.5 (30.7-43.1) 
55-64 10,987  232 2.3 (2.0-2.6) 2.1 (1.9-2.4)  2,931  460 16.7 (15.4-18.2) 15.8 (14.4-17.4) 
65-74 21,981  1,099 5.3 (5.0-5.6) 1.8 (1.7-1.9)  8,680  1,723 21.0 (20.1-21.9) 7.1 (6.8-7.4) 
75-84 24,155  2,843 12.5 (12.1-13.0) 1.6 (1.5-1.6)  11,931  3,227 28.8 (27.9-29.6) 3.7 (3.5-3.8) 
>85 9,268  2,400 27.3 (26.4-28.2) 1.4 (1.3-1.4)  4,554  1,915 44.3 (42.8-45.8) 2.3 (2.2-2.4) 
Total 70,981  6,651 9.9 (9.7-10.2) 1.6 (1.5-1.6)  29,086  7,464 27.2 (26.7-27.7) 3.7 (3.6-3.8) 
Precipitated AUR            
45-54 3,522  114 3.4 (2.9-4.1) 8.4 (6.9-10.1)  1,457  339 24.3 (22.1-26.6) 60.4 (54.2-67.2) 
55-64 5,496  235 4.5 (4.0-5.1) 4.3 (3.8-4.9)  3,240  808 26.0 (24.5-27.6) 25.1 (23.4-26.9) 
65-74 11,426  880 8.1 (7.6-8.6) 2.7 (2.6-2.9)  9,035  2,612 30.0 (29.1-31.0) 10.3 (9.9-10.7) 
75-84 14,869  2,571 18.1 (17.5-18.8) 2.3 (2.2-2.4)  13,279  5,140 40.5 (39.6-41.3) 5.2 (5.1-5.4) 
>85 7,578  2,778 38.0 (36.9-39.2) 2.0 (1.9-2.0)  6,077  3,205 54.7 (53.4-55.9) 2.8 (2.7-2.9) 
Total 42,891  6,578 16.1 (15.7-16.4) 2.3 (2.2-2.3)  33,088  12,104 38.1 (37.6-38.6) 5.0 (4.9-5.1) 
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4.1 Introduction and Objectives 
 
Many administrative databases have been developed throughout the world for 
health service planning and financial management.  Although most were never 
intended to be used for research and performance assessment, they have been 
recognised as a unique data source for descriptive and comparative studies of 
surgical outcomes in many countries. [Aylin, 2007; Sundararajan, 2004; Quan, 
2005; Jencks, 2003; Preen, 2006] 
 
Since 1989, the records of all patients admitted to NHS hospitals in England 
have been registered in the HES database.  Each record should include 
information on patients’ demographic characteristics as well as their main and 
supplementary diagnoses and operations.  Through linkage with mortality data 
from the Office for National Statistics, HES also contains information about date 
of death irrespective of whether patients died in hospital or after discharge.  
[Office for National Statistics; National Centre for Health Outcomes 
Development] 
 
When using administrative data for comparative purposes, it is essential to adjust 
for case-mix, as differences in patient characteristics may contribute to observed 
variations in health outcome. [Quan, 2005; Nuttall, 2006]    For this reason, a 
large number of instruments to identify comorbid conditions have been 
developed for use with administrative data. [Holman, 2005; Quan, 2005; 
Elixhauser, 1998; Fleming, 1999; von Korff, 1992]  Many of these instruments 
are adaptations of a comorbidity score, developed in 1987 for adult patients by 
Charlson and co-workers, [Charlson, 1987] using diagnosis codes from either the 
9th or 10th revisions of the International Classification of Diseases (ICD). [World 
Health Organisation, 1977; World Health Organisation, 1994] 
 
Most of these Charlson-based instruments were developed and validated in the 
United States [Deyo, 1992; Romano, 1993] or Canada. [Quan, 2005]  In these 
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countries, the main purpose of administrative databases is to guide 
reimbursement.  This provides strong incentives to record patient characteristics 
that maximise the apparent severity of patients’ health problems as well as to 
capture those procedures that are most financially rewarding.  Until 2007 in the 
United Kingdom, these incentives were far less powerful which makes it likely 
that coding practice was different.  Nevertheless, a recent study demonstrated 
that Charlson-based instruments that were derived in the United States – after 
translating ICD-9 into ICD-10 codes – were valid in identifying comorbidity in 
patients undergoing urological cancer surgery in England, although adjustment 
for comorbidity in this way had only a limited additional impact compared to 
adjusting for age and sex alone. [Nuttall, 2006] 
 
Encouraged by the results of this recent English study, a consensus group was 
convened at The Royal College of Surgeons of England (RCS).  The specific 
objectives of this consensus group were to agree general principles for 
identifying comorbidity in adult surgical patients and to develop the Charlson-
based ICD-10 comorbidity instrument for patients undergoing surgery in the 
United Kingdom. [Nuttall, 2006] 
 
In this chapter, we first present the comorbidity instrument developed by the 
consensus group (the RCS Charlson Score).  Second, we describe the validity of 
this instrument in terms of its association with known risk factors for comorbidity 
as well as its ability to predict post-operative mortality after a variety of common 
surgical procedures. 
 
 
4.2 Methods 
 
4.2.1 RCS Consensus Group 
A consensus group was convened in 2007 that consisted of five senior surgeons 
with a track record in research, audit and service evaluation representing 
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cardiothoracic, colorectal, orthopaedic, urological and vascular surgery, 
supported by methodologists with a background in clinical epidemiology and 
health services research (RCS Comorbidity Consensus Group; see Appendix 1).  
Before the meeting, the group received a document describing the 17 comorbid 
conditions that are included in the existing Charlson-based comorbidity 
instruments.  This document also contained an overview of the codes used in 
each of the five existing ICD-10 versions of these instruments. [Halfon, 2002; 
Nuttall, 2006; Quan, 2005; Sundararajan, 2004] 
 
The group’s decisions on which ICD-10 codes to include in the RCS Charlson 
Score were almost always based on consensus achieved through discussion.  
When consensus could not be reached a majority view was taken.  A draft of the 
RCS Charlson Score was sent to all group members and they were invited to 
suggest further revisions and as a result 19 minor changes were made. 
 
4.2.2 General principles for identifying comorbidity 
At the start of the meeting, the group discussed the challenges of identifying 
comorbidity using administrative data and the following general principles were 
agreed: 
1. A comorbid condition should be defined as “a coexisting but unrelated 
condition that may affect a patient’s prognosis in addition to the primary 
disease”. [Elixhauser, 1998; Feinstein, 1970]  By defining comorbidity based 
on its effect on a patient’s prognosis, the group distinguished comorbid 
conditions deemed to be of prognostic significance from “unimportant 
conditions”. 
2. Whenever possible, only the first three digits of ICD-10 codes (giving the core 
disease category) should be used to identify comorbidity for three reasons:  
use of three-digit codes would enhance the international transferability of the 
RCS Charlson Score; it would reduce the impact of coding errors that are 
most likely to occur in the fourth digit of ICD-10 codes (reflecting aetiology, 
anatomic site or severity), [Surjan, 1999; Stausberg, 2008] and coding 
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definitions that only use three-digit codes are more practical and user-
friendly. 
3. The original Charlson disease categories distinguished between mild and 
severe conditions.  This distinction is often difficult or even impossible to 
make on the basis of diagnosis codes available in administrative data and 
should therefore be avoided. 
4. The prognostic importance of some diseases has changed.  Therefore, 
comorbid conditions that were included in the original Charlson Score but that 
are no longer considered to have an important prognostic effect should be 
omitted.  Similarly, the weights assigned to each of the comorbid conditions in 
the original Charlson Score, reflecting their prognostic importance in the 
1980s, should not be used. 
5. Comorbidity should be sought from diagnosis codes in the record of the index 
admission (the hospital admission during which the procedure of interest was 
carried out) as well as from codes in the records of previous admissions. 
[Preen, 2006] 
6. Acute comorbid conditions (comorbidity with a sudden onset, such as acute 
myocardial infarction or stroke) should be sought in records of previous 
admissions only.  If these codes are present in the record of the index 
admission, it is not possible to determine whether they represent comorbidity 
or complications that have arisen during the process of care. 
7. Codes that represent very rare conditions (fewer than 10 hospital admissions 
in England each year) should not be used. 
8. Codes that represent paediatric conditions should be omitted given that the 
RCS Charlson Score is being developed for adult patients only. 
9. Procedure codes should not be used to identify comorbidity for two reasons: 
if comorbid conditions are clinically relevant it should be possible to identify 
them from the diagnosis codes alone; and procedure coding differs between 
countries and coding systems, and their inclusion would limit international 
applicability. 
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4.2.3 Development of RCS Charlson Score 
At the time of the consensus meeting (2007), five versions of Charlson-based 
ICD-10 comorbidity instruments were available, all using different coding 
schemes to identify comorbid conditions. [Halfon, 2002; Nuttall, 2006; Quan, 
2005; Sundararajan, 2004]  The consensus group considered all individual ICD-
10 codes of these five versions. 
 
An inclusive approach was followed whereby ICD-10 codes were included in the 
RCS Charlson Score if they appeared in at least one of the five versions and 
were considered to comply with the general principles described above. 
 
4.2.4 Validation of RCS Charlson Score 
We investigated to what extent the presence of comorbidity identified by the RCS 
Charlson Score was associated with age, sex and type of admission (elective 
compared to emergency).  We also investigated to what extent the presence of 
comorbidity was associated with poor outcomes such as increased length of 
hospital stay, augmented care use (time spent in a high dependency or intensive 
care unit), and in-hospital or 1-year mortality. 
 
Data were extracted from the HES database for all patients aged 45 years and 
over recorded as having had repair of an unruptured abdominal aortic aneurysm 
(AAA), aortic valve replacement (AVR), total hip replacement (THR) or TURP 
between 1st April 1999 and 31st March 2005.  These procedures were chosen as 
they are common, they are part of the Department of Health’s NHS Choices 
initiative, they vary in complexity and risk, and they are mostly carried out in 
elderly patients who have a range of comorbid conditions. [NHS Choices, 2008]   
 
We identified all patients who had AAA repair using the OPCS-4 (Office of 
Population, Censuses and Surveys Classification of Surgical Operations and 
Procedures – Fourth Revision) codes L18 (emergency replacement of 
aneurysmal segment of aorta), L19 (other replacement of aneurysmal segment 
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of aorta), L20 (other emergency bypass of segment of aorta) and L21 (other 
bypass of segment of aorta). [Office of Population, Censuses and Surveys, 1996]  
Because patients with a ruptured AAA have a poorer prognosis than those 
without, we excluded patients with evidence of vessel rupture using the following 
ICD-10 codes: I710 (dissection of aorta), I711 (thoracic aortic aneurysm, 
ruptured), I713 (abdominal aortic aneurysm, ruptured), I715 (thoracoabdominal 
aortic aneurysm, ruptured) or I718 (aortic aneurysm of unspecified site, 
ruptured). 
 
We identified all patients who had AVR using the OPCS-4 code K26 (plastic 
repair of aortic valve).  We excluded patients with evidence of congestive cardiac 
failure (CCF) in either the index or preceding hospital admissions using the 
following ICD-10 codes: I11 (hypertensive heart disease), I13 (hypertensive 
heart and renal disease), I255 (ischaemic cardiomyopathy), I42 
(cardiomyopathy), I43 (cardiomyopathy in diseases classified elsewhere), I50 
(heart failure) and I517 (cardiomegaly).  CCF is considered a comorbid condition 
according to the Charlson Score, but for patients having AVR its presence 
reflects disease severity rather than comorbidity. [Elixhauser, 1998] 
 
We identified all patients who had THR using the OPCS-4 codes W37 (total 
prosthetic replacement of hip joint using cement), W38 (total prosthetic 
replacement of hip joint not using cement) and W39 (other total prosthetic 
replacement of hip joint).  We excluded all patients with an ICD-10 code 
indicating fractured neck of femur (S72) in any diagnosis field of the index 
admission. 
 
We identified all patients who had a TURP for BPH using the OPCS-4 code M65 
(endoscopic resection of male bladder outlet).  We then deleted all admission 
records of patients with an ICD-10 diagnosis code C61 (prostate cancer) in any 
diagnosis field of any admission. 
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The index admission for all patients was defined as the first hospital admission 
with an episode that contained an OPCS-4 code for any of these procedures in 
the first four procedural fields.  We abstracted the following data from the records 
of these episodes: age, sex, admission and discharge dates, admission method 
(elective or emergency), all primary and secondary diagnoses and procedures, 
status at discharge (alive or dead), and time spent in augmented care. A unique 
patient identifier in HES (HESID) allowed us to link admission records belonging 
to the same patient across different years.  Mortality information from the Office 
for National Statistics allowed us to follow all patients until death or 31st March 
2006. [Office for National Statistics] 
 
A patient was considered to have a comorbid condition if an ICD-10 code 
included in the RCS Charlson Score was present in any of the first seven 
diagnosis fields of either the index admission or a hospital admission in the 
preceding year with the restriction that acute comorbid conditions (see Table 1) 
should have been recorded in previous admissions. 
 
We compared the characteristics of the patients and the outcome of their 
procedures in patients with and without comorbidity according to the RCS 
Charlson Score using t-tests for means and chi-squared tests for proportions. 
 
We used multivariable logistic regression to determine the importance of 
adjusting for comorbidity in prognostic models that predict in-hospital and 1-year 
mortality after surgery.  Comorbidity was represented in the logistic models as 
the number of comorbid conditions (0, 1, 2, 3 or more) that were identified with 
the RCS Charlson Score.  We also assessed the performance of models that 
only contained an indicator representing whether comorbidity was present or not 
(ignoring the number of comorbid conditions) as well as that of models that 
contained 14 indicators representing the presence of each of the individual 
comorbid conditions. 
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We evaluated the importance of adjusting for comorbidity by comparing the 
performance of four prognostic models: 
1. A “basic model” that included only age and sex. 
2. An “administrative model” that included age, sex, admission method (elective 
or emergency) and the number of emergency hospital admissions in the 
previous year. This model was intended to give an indication of the value of 
using administrative variables only. 
3. A “comorbidity model”: basic model plus RCS Charlson Score. 
4. A “combined model”: administrative model plus RCS Charlson Score. 
 
The performance of these four pre-specified models was evaluated separately 
for each procedure using the HES datasets.  The ability of each of the prognostic 
models to distinguish patients who died from those who did not (“discrimination”) 
was evaluated using the c-statistic that corresponds to the area under the 
receiver operator characteristic curves. [Fawcett, 2006; Hanley, 1982]  This c-
statistic is equivalent to the probability that the model will rank a randomly 
selected patient who dies higher than a randomly selected patient who does not 
die.  A c-statistic with a value of 0.5 indicates that the model discriminates no 
better than chance alone and a c-statistic with a value of 1.0 indicates perfect 
discrimination.  The c-statistics of the models were compared using a 
significance test that recognises that they were derived from the same rather 
than a different set of cases. [DeLong, 1988] 
 
The agreement between observed mortality and the expected mortality predicted 
by the prognostic models (“calibration”) was assessed graphically and tested 
with the Hosmer-Lemeshow goodness-of-fit statistics. [Hosmer, 1989] 
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4.3 Results 
 
4.3.1 Development of RCS Charlson Score 
The RCS Charlson Score that was developed on the basis of the general 
principles agreed by the consensus group is presented in full in Table 4.1.  It 
consists of 14 disease categories.  The original versions of Charlson-based ICD-
10 comorbidity instruments had 17 categories. [Halfon, 2002; Nuttall, 2006; 
Quan, 2005; Sundararajan, 2004]  We omitted peptic ulcer disease because it 
was no longer considered to be of prognostic importance with the advent of 
effective pharmacological treatments.  Mild liver disease and severe liver disease 
were combined as were diabetes with and without complications because these 
distinctions cannot be reliably made using HES data. 
 
As a result of using three-digit ICD-10 codes as much as possible, the coding 
algorithm of the RCS Charlson Score contained far fewer codes than any of the 
other Charlson-based ICD-10 comorbidity instruments. 
 
Seven acute conditions should only be counted as comorbidity if they occurred in 
the record of a previous hospital admission within the preceding 12 months (see 
codes indicated with an asterisk in Table 4.1). 
 
4.3.2 Validation of RCS Charlson Score 
The HES database contained records of 26,255 patients who had a repair of an 
unruptured AAA, 23,005 patients without evidence of CCF who had an AVR, 
238,999 patients who had a THR, and 135,490 patients who had a TURP 
between 1st April 1999 and 31st March 2005.  The characteristics of these 
patients as well as the outcomes of their surgery are presented in Table 4.2 
according to whether comorbidity was present or not. 
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Prevalence of comorbidity 
Of the patients who had AAA repair, 47.0% had at least one comorbid condition 
(29.0% had one, 11.8% two and 6.1% three or more) according to the RCS 
Charlson Score.  Corresponding figures were 36.0% for AVR (28.0% had one, 
6.7% two and 1.3% three or more), 19.4% for THR (16.2% had one, 2.6% two 
and 0.5% three or more), and 26.0% for TURP (14.7% had one, 7.8% two and 
3.6% three or more). 
 
Risk factors for comorbidity 
With the exception of patients undergoing AAA repair, patients with comorbidity 
tended to be older and more frequently admitted as an emergency (Table 4.2).  
The percentage of patients who were male did not systematically differ between 
those with and without comorbidity. 
 
Outcomes according to comorbidity 
For all four surgical procedures, time spent in augmented care as well as length 
of hospital stay was longer in patients with comorbidity compared to those 
without, although the difference in time spent in augmented care was not 
statistically significant for patients with TURP (Table 4.2).  For example, AVR 
patients with comorbidity spent on average more than one day longer in 
augmented care and almost three days longer in hospital than those without.  
Comorbidity seems to have the largest effect on time spent in augmented care in 
patients undergoing AAA repair and AVR and the strongest effect on length of 
stay in patients undergoing THR. 
 
The presence of comorbidity increased in-hospital and 1-year mortality for all 
procedures (Table 4.2).  Absolute differences in in-hospital mortality were 
considerably greater in patients undergoing AAA repair and AVR than in those 
undergoing THR and TURP.  The relative increases were greater for patients 
having THR (8-fold) and TURP (5-fold) than for AAA (2-fold) and AVR (2-fold).  
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Absolute differences in 1-year mortality were similar in magnitude across all four 
surgical procedures. 
 
Discrimination 
Four multivariable logistic regression models were used to determine the 
importance of comorbidity in predicting in-hospital (Table 4.3a) and 1-year 
mortality (Table 4.3b).  When adding comorbidity (represented as the number of 
comorbid conditions) to the basic and administrative models, we found that the c-
statistics increased significantly for all four surgical procedures (p always < 
0.001).  For the basic model, increases of the c-statistic varied from 0.04 to 0.07 
(compare basic and comorbidity models in Table 4.3a); for the administrative 
model corresponding increases varied from 0.03 to 0.04 (compare administrative 
and combined models in Table 4.3a).  The discriminatory ability of the models 
predicting 1-year mortality also increased when the number of comorbid 
conditions was included, although the increases in the c-statistic were slightly 
smaller (Table 4.3b). 
 
Calibration 
Visual inspection of the calibration plots of observed versus expected mortality 
according to deciles of risk showed good agreement between observed mortality 
and that predicted by the “combined model” for all four surgical procedures.  For 
patients having AVR, THR and TURP, the Hosmer-Lemeshow goodness-of-fit 
test confirmed good agreement with no statistically significant difference between 
observed and expected mortality (p>0.05).  However, for patients having AAA 
repair there was a statistically significant difference between observed and 
expected in-hospital mortality (p=0.002).  The large sample size resulted in a 
minor difference reaching statistical significance (see Figure 4.1). 
 
4.3.3 Use of RCS Charlson Score information 
The RCS Charlson Score is designed to be used as a count of the number of 
comorbid conditions (0, 1, 2, or 3 if there are three or more comorbid conditions).  
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When the comorbidity information was used in this way, we found moderate to 
very good discrimination of the combined models (c-statistics varied between 
0.70 and 0.87 according to procedure).  When comorbidity information was 
represented simply as the presence or absence of comorbidity (0 or 1), the 
discriminatory performance was slightly worse (c-statistics reduced by 0.01 for all 
four surgical procedures).  When each of the 14 individual comorbid disease 
categories was incorporated into the “combined model”, discrimination was 
slightly better (c-statistics increased by up to 0.02). 
 
 
4.4 Discussion 
 
The RCS Comorbidity Consensus Group developed and validated a comorbidity 
score for use with administrative data in the United Kingdom.  The RCS Charlson 
Score has a number of advantages over existing comparable comorbidity scores.  
First, it is shorter and based on a simpler coding philosophy that enhances 
coding accuracy and international transferability.  Second, it reflects our current 
understanding of the prognostic impact of comorbid disease.  Third, it explicitly 
aims to avoid misclassifying surgical complications as comorbidity.  We 
demonstrated using HES data for patients undergoing four common surgical 
procedures in England that the performance of this simplified score was at least 
as good as existing scores. [Quan, 2005] 
 
The RCS Charlson Score was developed on the basis of general principles 
agreed by the consensus group in advance.  The group felt that these principles 
should always be considered when existing instruments are updated or new 
ones developed. 
 
4.4.1 Methodological limitations 
Many of the comorbidity scores that have been developed for use with 
administrative data are based on the original Charlson Score. [Charlson, 1987]  
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As a result, a number of disease categories, such as neurological (for example, 
multiple sclerosis, Parkinson’s disease) and endocrine (for example, thyroid) 
disorders, are not included.  Although these diseases may be of significant 
prognostic importance, their prevalence is relatively low.  The consensus group 
felt that this trade-off between comprehensiveness and parsimony should be 
explicitly addressed in the further development of comorbidity scores. 
 
Secondly, the RCS Charlson Score was developed with surgical patients in mind 
and validated in patients undergoing elective surgery.  These patients constitute 
a highly selected group as surgery is only offered to patients who are deemed fit 
for the procedure.  Therefore, this score may perform differently in patients 
receiving other treatment and further evaluations of its performance are 
necessary. 
 
A third limitation is that each disease category is given an equal weight in the 
RCS Charlson Score, as it was designed to be used as a simple count of 
comorbid conditions.  We explored to what extent the performance of the RCS 
Charlson Score improved by assigning weights to each of the individual disease 
categories.  Including the individual comorbidity information in this way resulted 
in small improvements of discriminatory performance (c-statistic increased up to 
0.02). 
 
Fourth, a clinical coding audit programme demonstrated errors in 16.5% of the 
primary diagnosis and procedure codes. [PbR data Assurance Framework 
2007/08]  Furthermore, another recent study demonstrated differences in coding 
practices among hospitals. [Mohammed, 2009]  Our results are therefore likely to 
underestimate the strength of the associations between risk factors and 
prevalence of comorbidity and between comorbidity and clinical outcomes. 
 
Lastly, we evaluated the performance of various prognostic models, including 
those with RCS Charlson Score comorbidity information, using c-statistics to 
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measure discrimination.  However, for prognostic models that already contain 
standard risk factors and have reasonably good discriminatory power, very large 
independent associations of the new marker are required to produce 
meaningfully larger c-statistics.  Therefore, new methods to evaluate model 
performance have been developed and these may have better demonstrated the 
importance of comorbidity information in models that predict mortality after 
surgery. [Pencina, 2008] 
 
4.4.2 Validity of RCS Charlson Score 
We found that the presence of comorbidity according to the RCS Charlson Score 
was associated with known risk factors for comorbidity, such as age and type of 
admission, and with increased length of time spent in augmented care and in 
hospital, as well as higher mortality.  Inclusion of the RCS Charlson Score 
improved the performance of models for short-term outcomes (in-hospital 
mortality) as well as for outcomes in the more distant future (1-year mortality). 
 
The validity of the existing comorbidity instruments for ICD administrative data 
was demonstrated in a similar way in administrative databases in the United 
States, [Deyo, 1992; Romano, 1993] Canada, [Quan, 2005] Australia 
[Sundararajan, 2004] and Sweden. [Halfon, 2002]  Of these existing instruments, 
the most rigorously developed appears to be a Canadian version. [Quan, 2005]  
For example, its developers reviewed existing algorithms and extensively 
consulted clinical coders and clinicians.  We examined the performance of this 
Canadian instrument in the same HES dataset that we used to validate the RCS 
Charlson Score.  To ensure a fair comparison, we applied the ICD-10 codes in 
the Canadian instruments that relate to acute conditions only in records of 
preceding hospital admissions.  The performance of the Canadian instrument 
was comparable to that of the RCS Charlson Score (results not shown).  For 
example, discriminatory performance of models including comorbidity identified 
with the RCS Charlson Score or with the Canadian instrument differed at most 
by 0.01 in terms of the c-statistic.  This result has to be interpreted in the context 
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that the Canadian instrument contains about 50% more data fields than the RCS 
Charlson Score and a greater number of four-digit codes.  This comparison 
suggests that we have been successful in simplifying the comorbidity score for 
use in administrative data in the United Kingdom without diminishing its 
performance. 
 
Most of the existing comorbidity scores do not consider comorbidity information 
derived from records of previous hospital admissions. [Halfon, 2002; 
Sundararajan, 2004; Quan, 2005]  To improve the detection of comorbidity and 
to avoid using acute conditions that were recorded for the first time in the index 
admission, the consensus group felt that it was important to include the records 
of admissions in the preceding year.  An important consideration in this context 
was that HES and equivalent administrative databases in the United Kingdom do 
not have a “diagnosis-type” indicator specifying the timing of the diagnosis which 
could be used to determine whether acute diagnoses recorded for the index 
admission are comorbid conditions or complications arising from the surgical 
treatment. 
 
For example, in the 26,255 patients undergoing AAA repair, the RCS Charlson 
Score identified 974 patients (3.7%) with “old myocardial infarction” (I252) in the 
record of the index admission and 586 more patients (2.2%) with “acute 
myocardial infarction” (I21), “subsequent myocardial infarction” (I22) or “certain 
current complications following acute myocardial infarction” (I23) in records of 
hospital admissions in the preceding year.  In total 1,560 patients (5.9%) were 
identified as having had a myocardial infarction before they had their operation.  
If we had identified patients with myocardial infarction by applying all of these 
codes to the index admission record only, we would have found 1,940 (7.4%).  
The difference between these two results (1,560 and 1,940) includes those 
patients who developed a myocardial infarction as a complication during or after 
their surgery. 
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4.4.3 Implications 
A number of governmental initiatives in England emphasise the need to measure 
the quality of care of every provider in the NHS. [Darzi, 2008]  For example, 
information on key performance indicators will be published to inform clinicians, 
managers and providers as well as patients and the public.  It is generally 
accepted that this information needs to be robust, rigorous and risk-adjusted.  
HES has been recognised as a crucial data source for these “quality metrics” 
and the RCS Charlson Score should be considered as an instrument to identify 
comorbidity, especially when outcomes of surgical procedures are being 
evaluated. 
 
It has been recognised that the performance of comorbidity scoring instruments 
using administrative data differs across countries. [De Coster, 2006; 
Sundararajan, 2007]  We aimed to enhance the international transferability of the 
RCS Charlson Score by using three-digit codes as much as possible and 
avoiding the use of procedure codes.  Given the results of our comparison of the 
RCS Charlson Score with the most rigorously developed comorbidity instrument 
to date, [Quan, 2005] we feel that the RCS Charlson Score should also be 
considered for international comparisons. 
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4.5 Tables 
 
Table 4.1: The RCS Charlson Score indicating ICD-10 codes for 14 disease categories. 
 
Disease category ICD-10 codes 
Myocardial infarction I21*-I23*, I252 
Congestive cardiac failure I11, I13, I255, I42, I43, I50, I517 
Peripheral vascular disease I70-I73, I770, I771, K551, K558, K559, R02, Z958, Z959 
Cerebrovascular disease G45, G46, I60-I69 
Dementia A810, F00-F03, F051, G30, G31 
Chronic pulmonary disease I26, I27, J40-J45, J46*, J47, J60-J67, J684, J701, J703 
Rheumatalogical disease M05, M06, M09, M120, M315, M32-M36 
Liver disease B18, I85, I864, I982, K70, K71, K721, K729, K76, R162, Z944 
Diabetes mellitus E10-E14 
Hemiplegia or paraplegia G114, G81-G83 
Renal disease I12, I13, N01, N03, N05, N07, N08, N171*, N172*, N18, N19*, 
N25, Z49, Z940, Z992 
Any malignancy C00-C26, C30-C34, C37-C41, C43, C45-C58, C60-C76, C80-
C85, C88, C90-C97 
Metastatic solid tumour C77-C79 
AIDS / HIV B20-B24 
* Asterisked codes represent acute conditions that should be used to define comorbidity only if present in the record 
of a previous hospital admission within the preceding 12 months. 
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Table 4.2: Associations between comorbidity identified by the RCS Charlson Score and 
risk factors for comorbidity and clinical outcomes. 
 
 
Procedure No comorbidity 
(RCS Charlson Score = 0) 
Comorbidity 
(RCS Charlson Score ≥ 1) 
P-value 
AAA (Unruptured)      
Patients, no. (%) 13,920 (53.0) 12,335 (47.0) - 
Mean age, years (SD) 71.7 (7.9) 70.7 (8.3) <0.001 
Male sex, no. (%) 11,446 (82.2) 10,096 (81.9) 0.434 
Emergency admissions, no. (%) 2,830 (20.3) 2,368 (19.2) 0.021 
Augmented care, mean, days (SD) 4.5 (5.5) 5.7 (7.8) <0.001 
Length of stay, mean, days (SD) 13.2 (12.4) 15.4 (15.7) <0.001 
In-hospital mortality, no. (%) 736 (5.3) 1,199 (9.7) <0.001 
*1-year mortality, no. (%) 1,265 (10.7) 2,024 (20.0) <0.001 
AVR (No CCF)      
Patients, no. (%) 14,719 (64.0) 8,286 (36.0) - 
Mean age, years (SD) 68.5 (9.5) 69.0 (8.9) <0.001 
Male sex, no. (%) 8,854 (60.2) 5,047 (60.9) 0.279 
Emergency admissions, no. (%) 2,244 (15.2) 1,795 (21.7) <0.001 
Augmented care, mean, days (SD) 3.2 (3.8) 4.4 (7.6) <0.001 
Length of stay, mean, days (SD) 13.4 (11.7) 16.2 (15.7) <0.001 
In-hospital mortality, no. (%) 392 (2.7) 507 (6.1) <0.001 
*1-year mortality, no. (%) 762 (6.2) 838 (13.0) <0.001 
THR      
Patients, no. (%) 192,733 (80.6) 46,266 (19.4) - 
Mean age, years (SD) 69.8 (9.8) 71.3 (9.6) <0.001 
Male sex, no. (%) 72,339 (37.5) 18,749 (40.5) <0.001 
Emergency admissions, no. (%) 9,556 (5.0) 4,696 (10.2) <0.001 
Augmented care, mean, days (SD) 1.7 (2.1) 2.0 (2.3) <0.001 
Length of stay, mean, days (SD) 10.9 (9.8) 14.0 (15.7) <0.001 
In-hospital mortality, no. (%) 461 (0.2) 755 (1.6) <0.001 
*1-year mortality, no. (%) 3,559 (2.2) 2,946 (8.0) <0.001 
TURP      
Patients, no. (%) 100,199 (74.0) 35,291 (26.0) - 
Mean age, years (SD) 70.8 (8.6) 73.4 (8.1) <0.001 
Emergency admissions, no. (%) 7,987 (8.0) 3,472 (9.8) <0.001 
Augmented care, mean, days (SD) 0.7 (2.6) 0.9 (2.7) 0.433 
Length of stay, mean, days (SD) 5.1 (4.9) 6.6 (9.4) <0.001 
In-hospital mortality, no. (%) 84 (0.1) 164 (0.5) <0.001 
*1-year mortality, no. (%) 2,325 (2.7) 2,701 (9.1) <0.001 
*1-year mortality is calculated after excluding patients in the final year of the study that did not have at least 1 year’s complete 
follow-up. 
 
 
 
Table 4.3a: Discriminatory ability of prognostic models that predict in-hospital mortality after each of the four surgical procedures. 
 
 
 Basic 
Age and sex 
Administrative 
Age, sex, admission 
method and number of 
emergency admissions in 
preceding year 
Comorbidity 
Age, sex and RCS 
Charlson Score 
Combined 
Age, sex, admission method, 
number of emergency 
admissions in preceding year 
and RCS Charlson Score 
 c-statistic (95% CI) c-statistic (95% CI) c-statistic (95% CI) c-statistic (95% CI) 
AAA 0.62 (0.61-0.63) 0.66 (0.65-0.68) 0.66 (0.65-0.67) 0.70 (0.68-0.71) 
AVR 0.61 (0.59-0.62) 0.67 (0.65-0.69) 0.67 (0.66-0.69) 0.71 (0.69-0.72) 
THR 0.78 (0.76-0.79) 0.83 (0.81-0.84) 0.84 (0.83-0.85) 0.87 (0.85-0.88) 
TURP 0.76 (0.74-0.79) 0.82 (0.79-0.84) 0.83 (0.80-0.85) 0.86 (0.83-0.88) 
AAA = abdominal aortic aneurysm repair (unruptured), AVR = aortic valve replacement, THR = total hip replacement and TURP = transurethral resection of the prostate. 
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Table 4.3b: Discriminatory ability of prognostic models that predict 1-year mortality after each of the four surgical procedures. 
 
 
 Basic 
Age and sex 
Administrative 
Age, sex, admission 
method, number of 
emergency admissions in 
preceding year 
Comorbidity 
Age, sex and RCS 
Charlson Score 
Combined 
Age, sex, admission method, 
number of emergency 
admissions in preceding year 
and RCS Charlson Score 
 c-statistic (95% CI) c-statistic (95% CI) c-statistic (95% CI) c-statistic (95% CI) 
AAA 0.62 (0.61-0.63) 0.66 (0.65-0.67) 0.67 (0.66-0.68) 0.70 (0.69-0.70) 
AVR 0.61 (0.60-0.63) 0.65 (0.64-0.67) 0.67 (0.66-0.68) 0.69 (0.68-0.70) 
  THR 0.72 (0.72-0.73) 0.77 (0.77-0.78) 0.77 (0.77-0.78) 0.80 (0.79-0.80) 
TURP 0.70 (0.70-0.71) 0.76 (0.75-0.77) 0.73 (0.73-0.74) 0.77 (0.76-0.78) 
AAA = abdominal aortic aneurysm repair (unruptured), AVR = aortic valve replacement, THR = total hip replacement and TURP = transurethral resection of the prostate. 
 
Figure 4.1: Comparison of observed (grey) and expected (black) in-hospital mortality in 
patients undergoing unruptured AAA repair according to deciles of risk.  Expected 
mortality is predicted with the “combined model” (see text for further explanation). 
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Section 3 
 
 
 
Evaluating the management options for men with acute urinary 
retention 
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Chapter 5 
 
 
Review of minimally invasive treatment of acute urinary 
retention 
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5.1 Objectives 
 
To enable selection of the most appropriate treatment for a man with AUR it is 
important to understand the effectiveness, durability and safety of the available 
options.  This chapter provides an overview of some of the minimally invasive 
treatment options for men with AUR, most of which have been recently subjected 
to evaluation by systematic literature review. 
 
 
5.2 Minimally invasive treatment of acute urinary retention 
 
5.2.1 Transurethral microwave thermotherapy 
Heating of the prostate using microwaves causes tissue ablation thereby 
relieving bladder outlet obstruction secondary to BPH. [Yerushalmi, 1985]  Early 
microwave devices heated the prostate to temperatures of between 40 and 
45°C.  Although patients reported some symptomatic improvement histological 
studies revealed that these temperatures were inadequate to cause cell death. 
[Montorsi, 1992]  At temperatures greater than 45°C cellular apoptosis and 
necrosis occur.  Therefore, the term hyperthermia is used to describe treatments 
producing prostatic temperatures of less than 45°C, and thermotherapy applied 
to those that achieve temperatures above this threshold.  Histological studies 
have demonstrated that the amount of tissue necrosis is proportional to the 
temperature reached within the prostate and the duration for which it is 
sustained. [Devonec, 1993] 
 
Several thermotherapy devices have been developed for the treatment of BPH.  
These include CoreTherm (ProstaLund, Sweden), Urowave (Dornier Medical 
Systems), Prostcare (HighTechCare, France), Prostatron (EDAP Technomed 
Medical Systems, France) and Targis (Urologix, United States).  While these 
differ with respect to how they deliver the energy and monitor its effects, they are 
conceptually the same.  All require the insertion of a specially designed urethral 
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catheter that locates a microwave antenna within the prostate.  The antenna 
produces microwaves that pass into the prostate tissue where they are absorbed 
causing heat production and cellular destruction.  Treatments typically last 
between 10 minutes and one hour with some devices tailoring the duration of 
treatment specifically to the individual.  Thermotherapy causes a considerable 
amount of tissue oedema that requires a period of urethral catheterisation after 
the procedure, typically between one and two weeks. 
 
A recent systematic review identified six distinct randomised controlled trials that 
compared thermotherapy to TURP in men with urinary symptoms attributed to 
BPH. [Hoffman, 2007]  The pooled mean symptom score for men receiving 
thermotherapy decreased by 65% in 12 months compared to 77% for men 
undergoing TURP.  A mean increase in peak urinary flow rate of 70% was noted 
following thermotherapy compared to 119% after TURP.  While re-treatment 
rates were significantly higher after thermotherapy, adverse events were 
generally lower compared to TURP. 
 
The same systematic review identified seven randomised controlled trials 
incorporating 850 patients that compared thermotherapy to sham treatment. 
[Hoffman, 2007]  The pooled mean symptom score for men undergoing 
thermotherapy decreased by 50% in 3 to 6 months (21.4 to 10.8) compared to 
41% (21.3 to 12.6) in men undergoing sham treatment.  However, men 
undergoing thermotherapy were significantly more likely than those undergoing 
sham treatments to experience urinary retention, dysuria and haematuria. 
 
A randomised controlled trial that compared thermotherapy to alpha-receptor 
blockade using terazosin demonstrated significant improvements in International 
Prostate Symptom Scores (IPSS), peak urine flow rates and quality of life scores 
in both groups at six months. [Djavan, 2001]  The magnitude of the improvement 
was significantly greater in the thermotherapy group than in the terazosin group.  
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Furthermore, treatment failure rates in those receiving medical therapy were 
seven times those seen in the thermotherapy group at 18 months. 
 
Thermotherapy appears to be an effective outpatient treatment for BPH that has 
fewer adverse events than TURP.  However, TURP offers greater improvement 
in urinary symptoms and peak urine flow rates and fewer patients may require 
re-treatment than those who have thermotherapy. 
 
 
5.2.2 Transurethral needle ablation 
Transurethral needle ablation (TUNA) uses radiofrequency energy to cause 
heating and destruction of prostatic tissue.  Radio waves are delivered to the 
prostate by means of two sheathed needles placed within the prostate.  The 
procedure can be performed using local anaesthesia, often with sedation, in a 
similar manner to transrectal prostate biopsy.  Preservation of the prostatic 
urothelium minimises irritative voiding, haematuria, and urinary retention after the 
procedure.  A catheter is normally left in place for between 1 and 3 days after 
treatment to allow procedure-related oedema to resolve. 
 
A recent meta-analysis assessed the effectiveness of TUNA. [Boyle, 2004]  Two 
randomised controlled trials, two comparative studies and nine case series were 
identified and considered suitable for inclusion.  A total of 1,244 patients had an 
evaluable IPSS and estimates of maximum urine flow rates were given for 1,331 
patients.  TUNA was found to reduce IPSS by a mean 12.1 points (standard 
error of mean (SEM) 0.43) and increase maximum urine flow rates by a mean 
5.1ml/s (SEM 0.48) or approximately 70% from baseline at 1 year.  However, 
significantly greater improvements in symptoms and urine flow rates were 
observed after TURP.  IPSS decreased by 15.6 points (SEM 0.66) and maximum 
urine flow rates increased by 10.7ml/s (SEM 0.71).  Assessment at 5 years 
suggested these improvements were durable. 
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Transient dysuria and haematuria are commonly reported after TUNA.  A 
randomised controlled trial comparing TUNA with TURP reported fewer adverse 
events with TUNA. [Hill, 2004]  Rates of retrograde ejaculation, erectile 
dysfunction, urinary incontinence and stricture formation were less after TUNA 
than TURP.  However, re-treatment rates were higher after TUNA than TURP 
and 13.8% of TUNA patients required further intervention within 5 years. 
 
A single treatment with TUNA may provide a level of efficacy approaching that of 
TURP but with fewer complications.  TUNA may be performed using local 
anaesthesia, does not require hospitalisation and allows the patient to rapidly 
return to normal function.  Symptomatic improvement after TUNA may not be as 
durable as TURP and high re-treatment rates may limit its cost-effectiveness. 
[Rosario, 2007] 
 
 
5.2.3 Laser treatments 
The use of lasers to treat BPH has been explored since the 1990s.  Several 
different devices have been developed including the Neodymium:YAG, 
Holmium:YAG, and the Potassium-Titanyl-Phosphate (KTP) (GreenLight) lasers.  
Lasers produce two main tissue effects - coagulation and vaporisation.  At lower 
power settings, prostatic tissue is heated to temperatures of up to 100°C which 
causes coagulation and subsequently sloughing of the necrotic tissue.  
Temperatures of 300-400°C are achieved at higher power settings with 
consequent vaporisation and the immediate reduction in prostate bulk. 
 
The Neodymium:YAG laser is most commonly used for its coagulative effect 
although higher power settings do cause tissue vaporisation.  Examples of 
treatments which utilise the neodymium laser include visual laser ablation of the 
prostate (VLAP), contact laser ablation of the prostate (CLAP), and interstitial 
laser coagulation of the prostate (ILCP). 
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The ability of the holmium laser to cause both cutting and coagulation of soft 
tissues has led to the development of resection and enucleation techniques in 
addition to laser ablation of the prostate (HoLAP).  Holmium laser resection of 
the prostate (HoLRP) involves dissection of the gland to the capsule with its 
subsequent removal from the bladder in pieces.  Holmium laser enucleation of 
the prostate (HoLEP) uses a retrograde approach to dissect the prostate as far 
as the capsule followed by the introduction of a mechanical morcellator which 
makes tissue retrieval easier.  These techniques can be used to treat very large 
glands, up to 100ml and 200ml respectively. 
 
A recent systematic review and meta-analysis assessed the safety and 
effectiveness of HoLEP compared to TURP. [Tan, 2007]  The literature search 
and selection process identified four distinct randomised controlled trials that 
examined a total of 460 patients having either HoLEP (n=232) or TURP (n=228).  
Meta-analysis showed no statistically significant difference between HoLEP and 
TURP in terms of symptomatic improvement or urine flow rates at 6 and 12 
months follow-up.  While TURP was associated with reduced operating time, 
HoLEP was associated with significantly less blood loss, catheterisation time and 
length of hospital stay.  However, the short follow-up of patients in these studies 
limited conclusions on the durability of HoLEP. 
 
Another systematic review identified randomised controlled trials that compared 
laser prostate treatments to control interventions. [Hoffman, 2004]  Laser 
treatments were compared to TURP in 16 randomised controlled trials, two trials 
compared laser prostatectomy to transurethral electro-vaporisation of the 
prostate (TUVP) and one study each compared laser surgery to thermotherapy 
and open prostatectomy.  Urinary symptom scores were reduced by about 70% 
and flow rates generally doubled after laser treatment.  These improvements 
were comparable to those seen following TURP although six studies found 
statistically better results after TURP.  Hospital length of stay was significantly 
less following laser treatment compared to TURP and length of catheterisation 
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was less following contact laser treatments but longer after non-contact laser 
treatments than TURP.  Adverse events including transfusion, clot retention, 
strictures and TUR syndrome occurred less frequently after laser therapy than 
TURP.  Re-operation rates were, however, found to be greater after laser 
treatments than TURP within the first 12 months. 
 
Photoselective vaporisation of the prostate (PVP) represents one of the latest 
developments in laser prostate surgery.  The potassium-titanyl-phosphate (KTP) 
or GreenLight® laser emits laser energy that is absorbed by haemoglobin in red 
blood cells.  This causes rapid heating and vaporisation of the targeted tissue as 
well as coagulation of blood vessels.  The procedure requires general or spinal 
anaesthesia.  Preliminary data from a recent randomised controlled trial that 
compared PVP to TURP showed equivalent improvements in urinary flow rates 
and symptoms with reduced length of stay, length of catheterisation and adverse 
events. [Bouchier-Hayes, 2006] 
 
The heterogeneity of the various laser techniques and different laser devices 
makes generalisation of their safety and effectiveness difficult.  Laser treatments 
do seem to confer a shorter length of hospital stay and have fewer complications 
than TURP.  However, initial costs may be greater than those of conventional 
surgery and there is some evidence that re-treatment rates are higher.  General 
or regional anaesthesia is usually required which may limit their role in treating 
frail patients or those with significant comorbidity.  Laser resection and 
enucleation techniques have the advantage over other minimally invasive 
procedures of providing a specimen for histological analysis. 
 
In summary, there appears to be a balance between the effectiveness and 
durability of minimally invasive prostate treatments on the one hand, and their 
associated peri-operative morbidity and safety on the other.  Therefore, it is 
important to assess each patient’s individual circumstances when considering 
treatment options.  For example, an elderly patient with significant comorbidity 
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might be willing to accept a less durable and even less effective treatment if it 
allows spontaneous voiding and a quick return to normal activity.  A young man 
may also choose a potentially less durable treatment, accepting the likely need 
for further intervention, if the risks associated with the more invasive alternative 
can be avoided or at least deferred.   
 
The subsequent two chapters evaluate the effectiveness, durability and safety of 
prostatic stents and explore their role as a minimally invasive prostate treatment. 
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Chapter 6 
 
 
The Memokath stent for benign prostatic hyperplasia: a 
systematic review of the literature 
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6.1 Introduction and Objectives 
 
Many of the minimally invasive treatments described in Chapter 5 are designed 
to reduce the volume of the prostate and thereby relieve obstruction.  An 
alternative to removing tissue is to use a prostatic stent to hold open the 
obstructing prostate and bladder neck. 
 
In 1980, Fabian described a method of placing a stent in the prostatic urethra to 
relieve obstruction. [Fabian, 1980]  Stents that allow epithelial incorporation were 
designed to provide a permanent treatment for BPH.  Despite the theoretical 
advantages of stent incorporation, rates of infection, encrustation and migration 
remained high. [Bajoria, 1995]  Also, epithelial in-growth can cause luminal 
narrowing to an extent that requires stent removal which can be difficult and 
usually requires general anaesthesia. 
 
Consequently, another type of stent was developed.  These stents, which sit 
freely within the prostatic urethra, were initially designed to provide short term 
relief from bladder outlet obstruction. [Fabian, 1980]  More recently, some groups 
of patients with BPH at high surgical risk have been treated long-term using 
these non-epithelialising stents.  The stent of this type most commonly used in 
practice is the Memokath. 
 
The Memokath is manufactured from a nickel-titanium alloy that has the property 
of ‘shape-memory’.  ‘Shape-memory’ describes a process by which a deformed 
piece of the alloy is restored to its original shape by heating.  When a Memokath 
stent is positioned in the prostatic urethra, it is flushed with warm saline which 
causes it to expand, thereby ‘locking’ it into position.  Flushing with cold saline 
renders the stent soft which facilitates its removal.  The first generation of 
Memokath stent expanded along its entire length but problems were experienced 
with migration. [Nordling, 1991]  The second generation of Memokath has been 
available since 1992 and expands only at its distal end. 
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There have been a number of reviews of prostatic stents since their introduction 
25 years ago.  However, these reviews are not comprehensive and may present 
only the trial data which supports the author’s opinion.  An objective appraisal of 
the evidence can only be achieved by its systematic evaluation.  A systematic 
review also allows deficiencies in the evidence base to be identified and serves 
to highlight areas where further research is required.  This is the first systematic 
literature review to assess the safety, effectiveness and durability of the second 
generation Memokath stent for the management of BPH. 
 
 
6.2 Methods 
 
Inclusion and exclusion criteria.  We included studies of any design that used the 
second generation Memokath stent in men with BPH.  Only studies published 
after 1992 were included.  We excluded review articles, comments, editorials and 
case reports, in-vitro or animal experiments, and studies pertaining to the 
exclusive use of other stents or describing alternative procedures using the 
Memokath. 
 
Search strategy.  We searched Medline and Embase databases for papers 
published before March 2005 (see Appendix 2).  Additional literature was sought 
from the reference lists of all identified studies and the bibliographies of six 
recent review articles. [Harboe, 2004; Kapoor, 2000; Nordling, 1998; Oesterling 
1995; Ogiste, 2003, Van Dijk, 2003]  The manufacturer of the Memokath stent 
was asked to identify additional published or unpublished research.  None of the 
additional references were published in journals that were indexed in the 
databases.  No language restrictions were imposed. 
 
Outcomes.  We abstracted information on the frequency of complications that 
required stent removal, replacement or repositioning (treatment failure) as well 
as on the frequency of minor complications that did not require stent removal.  
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The severity of symptoms before and after stent insertion was assessed using 
urological symptom scores.  Changes in urodynamic indices were also assessed 
before and after stent insertion.  
 
Data extraction and assessment of methodological quality.  Titles and abstracts 
identified by the search were independently assessed for inclusion by two 
reviewers (J Armitage and A Rashidian).  All articles that were potentially 
relevant were obtained and the inclusion was assessed again after reading full 
papers.  Data were then independently extracted by the same two reviewers and 
presented in structured tables.  This data included information on study design, 
population characteristics and outcomes.  Any disagreements were resolved by 
discussion and consultation with a third reviewer (J van der Meulen).  Missing 
and additional information was sought from the authors. 
 
The quality of identified studies was appraised using criteria developed from 
published frameworks for the assessment of methodological quality (see 
Appendix 3). [Downs, 1998; Khan, 2001; Lohr, 2004] 
 
Analysis.  We calculated immediate and subsequent treatment failure rates; the 
mean change in symptom score with stent insertion was presented graphically 
for each study. 
 
 
6.3 Results 
 
Literature search.  The database search identified 526 articles, of which 497 
were excluded after assessment of their titles and abstracts (Figure 6.1).  The 
complete manuscripts of 29 studies were assessed, four of which met the 
inclusion criteria. [Kawakami, 2003; Matsuzaki, 2004; Perry, 2002; Poulsen, 
1993]  Bibliography review and communication with the stent manufacturer 
retrieved a further 33 studies.  If these additional studies were presented in 
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abstract format only, the authors were contacted for further information.  As a 
result, a further 10 studies were included in the review. [Booth, 1997; 
Eichenauer, 1998; Hamasaki, 2002; Itoh, 1999; Kiyota, 1994; Kuriki, 1995; 
Melissourgos, 1999; Mishra, 2004; Rathenborg, 2001; Sumura, 2002] 
 
Characteristics of included studies.  The literature search identified 14 case 
series (Table 6.1). [Kawakami, 2003; Matsuzaki, 2004; Perry, 2002; Poulsen, 
1993; Booth, 1997; Eichenauer, 1998; Hamasaki, 2002; Itoh, 1999; Kiyota, 1994; 
Kuriki, 1995; Melissourgos, 1999; Mishra, 2004; Rathenborg, 2001; Sumura, 
2002]  Study size was generally small with less than 50 participants in 11 of the 
14 case series. 
 
Quality assessment.  The methodological quality of the studies was poor.  For 
example, few authors clearly outlined the study objectives or the outcomes in 
which they were interested.  Statistical methods other than basic descriptive 
approaches were seldom employed and, if they were, insufficient detail was 
provided to allow the reader to be certain that their use was appropriate.  Only 
five studies gave estimates of the statistical uncertainty of their results.  The 
funding source was made explicit in only one study. 
 
On the other hand, most studies made their inclusion criteria explicit and defined 
their study population characteristics.  The majority defined recruitment periods 
clearly and reported major adverse events. 
 
Patient demographics.  In total, 839 patients were included and all of these 
seemed to be at high surgical risk.  Stents were inserted for LUTS or urinary 
retention.  Only one study clearly differentiated between acute and chronic 
urinary retention. [Mishra, 2004]  The pathogenesis of bladder outlet obstruction 
was BPH in the majority of cases.  Five studies included some patients with 
prostatic carcinoma (28% or less where stated). [Perry, 2002; Eichenauer, 1998; 
Hamasaki, 2002; Itoh, 1999; Sumura, 2002] 
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Treatment failure.  All the studies reported treatment failure (complications which 
required stent removal, replacement or repositioning) as an outcome (Table 6.2).  
Immediate failure occurred in 11 of the 311 patients (4%) for whom this 
information was available.  Immediate failure seemed to happen because of 
incorrect stent length or placement. [Poulsen, 1993; Eichenauer, 1998; 
Hamasaki, 2002]  The frequency of subsequent stent failure could not be derived 
as insufficient information was given on the timing of failure.  However, it was 
clear that stent migration was the most commonly reported cause of subsequent 
failure. 
 
Reported failure rates varied widely across the studies.  Two studies reported no 
stent failure after 8 weeks and 14 months (median) of follow-up. [Kawakami, 
2003; Matsuzaki, 2004]  The highest failure rate was 48% but the follow-up 
period in this study was not defined. [Mishra, 2004]  The second highest failure 
rate was 41% with patients followed up for a mean of 7 months. [Kiyota, 1994] 
 
Minor complications were inconsistently reported and little information was given 
on the timing of these events.  Those most commonly reported appeared to be 
urinary incontinence, infection and haematuria. 
 
Urological symptoms.  Changes in urological symptom score associated with 
stent insertion were reported in seven studies.  Five studies used the 
International Prostate Symptom Score (IPSS), [Matsuzaki, 2004; Perry, 2002; 
Eichenauer, 1998; Kiyota, 1994; Sumura, 2002] one used the Madsen-Iversen 
score, [Itoh, 1999] and one study [Kuriki, 1995] purported to have used the IPSS 
score but their reported values deviated from those accepted in the original 
definition. [Barry, 1992] 
 
All seven studies reporting symptom scores noted a reduction in symptoms 
following stent implantation.  Stent insertion was associated with a reduction in 
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IPSS of between 11 and 19 points, and a reduction in Madsen-Iversen score of 9 
points, but assessment was made at different times after stent placement (Figure 
6.2). 
 
Only three of the five studies that used the IPSS reported statistical parameters.  
The first of these studies compared the mean IPSS of a group of 150 patients 
before stent insertion with the mean of another group of 151 patients after the 
procedure (within 3 months). [Perry, 2002]  It reported a statistically significant 
reduction of 12 points, but seems to have used inappropriate statistical tests 
(paired t-test).  This study also claimed that the reduction in IPSS was durable 
for those patients that were followed for longer periods.  Another study reported 
a statistically significant reduction in IPSS of 11 points at 4 weeks compared with 
the pre-stent score (p<0.05) but said that the difference was no longer significant 
after 8 weeks. [Matsuzaki, 2004] Another observed a reduction in IPSS of 19 
points which was reported as statistically significant at 12 weeks following stent 
placement (p<0.05) but not after 24 weeks. [Sumura, 2002] 
 
Eight studies assessed changes in urodynamic indices.  Changes in the 
maximum urine flow rate was reported in seven studies, [Matsuzaki, 2004; 
Poulsen, 1993; Eichenauer, 1998; Itoh, 1999; Kiyota, 1994; Kuriki, 1995; 
Melissourgos, 1999] in mean flow rate in two, [Matsuzaki, 2004; Itoh, 1999] in 
post-void residual in four [Matsuzaki, 2004; Itoh, 1999; Melissourgos, 1999; 
Sumura, 2002] and in total voided urine volume in one study. [Poulsen, 1993]  
Increases in maximum urine flow rate, mean flow rate and total voided urine 
volume, and decreases in post-void residual urine were noted in all studies 
reporting the particular outcomes.  The increases in maximum urine flow rate 
associated with stent insertion ranged from 3 to 11 ml/sec although the time of 
assessment after placement varied. 
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6.4 Discussion 
 
This is the first systematic literature review of the safety, effectiveness and 
durability of the Memokath stent in patients with BPH at a high surgical risk.  The 
Memokath stent appears to be safe and effective.  Only 4% of patients had an 
unsuccessful initial insertion of Memokath.  The reduction in IPSS associated 
with the insertion of a Memokath is comparable to that seen after TURP. 
[Flanigan, 1998]  However, the follow-up is inconsistent and unreliable which 
means that conclusions on the durability of the Memokath cannot be drawn. 
 
There are no studies that compare the Memokath stent with alternative 
treatments for patients with LUTS or AUR.  The studies that we could include in 
this review are case series of generally poor methodological quality. 
 
At least 20 other types of prostatic stent can be identified.  The quality of the 
evidence on their performance in men with BPH appears to be no better than for 
the Memokath stent.  In the United States, most experience has been gained 
with the UroLume.  The use of the Memokath stent has been confined to Europe.  
Bioabsorbable and silicone stents have also been used for men with BPH, but 
these may be considered more suitable for short-term use, for example, to 
evaluate the potential benefit of a TURP or to maintain luminal patency 
immediately after other minimally invasive treatments for BPH. 
 
Our findings suggest that a patient can expect symptomatic improvement after 
Memokath stent insertion of a magnitude that is comparable to that seen after 
surgery. [Flanigan, 1998]  However, the evidence on symptom improvement is 
incomplete and imperfect.  For example, the timing of the IPSS measurements 
was sometimes not given, [Perry, 2002; Eichenauer, 1998] essential statistical 
parameters were not presented, [Matsuzaki, 2004; Perry, 2002; Eichenauer, 
1998; Kiyota, 1994; Sumura, 2002] and different patients were included in IPSS 
results obtained before and after stent insertion. [Perry, 2002]  Furthermore, one 
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study used IPSS estimated by the carers of patients with dementia, an approach 
that lacks validity. [Perry, 2002]  Despite these limitations, the insertion of a 
Memokath stent seems to result in a substantial improvement in symptoms and 
this finding is consistent between the studies. 
 
The studies included in this review looked at a heterogeneous group of patients.  
Patients were treated with a stent for both LUTS and urinary retention (acute and 
chronic).  The pathogenesis of obstruction was predominantly BPH but five 
studies also assessed patients with carcinoma of the prostate.  This 
heterogeneity may explain some of the observed differences between the 
studies’ outcomes. 
 
A feature that all the patients had in common was that they were all considered 
to be at high surgical risk and would probably have been offered a long-term 
catheter had they not been treated with a Memokath.  The complications 
associated with long-term catheterisation are well documented [Kohler-Ockmore, 
1996] and when considered in this context a Memokath stent may provide an 
attractive alternative for these patients. 
 
Our review highlights the need for further research.  First, a high quality 
observational study would provide information on the timing of treatment failure 
which would allow assessment of the durability of the Memokath stent.  
Furthermore, collection of detailed information on patient characteristics before 
insertion would contribute to the identification of patients who would benefit most 
from a Memokath stent.  Second, a randomised controlled trial would provide 
valid evidence on the safety and effectiveness of a stent compared with other 
treatment modalities.  However, the difficulties in designing such a trial should 
not be underestimated.  These include the definition of the comparison group as 
well as the nature and timing of the outcome assessment.  For example, should 
stents be compared with TURP?  On the basis of the findings of this review a 
more appropriate comparator is likely to be an indwelling urethral or suprapubic 
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catheter.  Also, how should the short-term morbidity associated with TURP or 
major stent complications be balanced against longer term symptom 
improvement? 
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6.5 Tables and figures 
 
Figure 6.1: Summary of Memokath study selection process 
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Titles and abstracts 
identified by database 
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Different stent  n=25 
Full papers reviewed 
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Abstract only 
(insufficient detail) n=3 
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Figure 6.2: Changes in symptom score with Memokath insertion (A) IPSS, (B) Madsen-
Iversen, indicating study size, the number of patients assessed if stated, and the time of 
assessment after stent insertion. 
 
 
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
Perry 2002 Eichenauer 1998 Kiyota 1994 Matsuzaki 2004 Sumura 2002 
IPSS 
Before After A 
When IPSS assessed 
           < 3 months   3-6 months  3 months                8 weeks                12 weeks 
Study size           n=211    n=86  n=17                n=15             n=25 
Number of patients assessed 
   Before           n=150    ?  ?                n=7              n=12 
   After           n=151    ?  ?                n=7              n=9 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
Itoh 1999 
Madsen- 
Iversen  
Score 
Before 
When symptoms assessed 
          < 3 months 
Study size          n=22 
Number of patients assessed 
    Before          n=9 
    After          n=9 
 
B
 
After 
 97 
Table 6.1: Characteristics of included studies 
 
Reference Country Type of 
publication 
Quality 
score 
(max 18) 
Participant characteristics 
 
 
    Number of 
participants 
Mean/Median 
age (range) 
Stent 
indication 
Pathology Mean/Median follow-
up (range) 
 
 
Booth 1997 
 
UK 
 
Journal 
Article 
 
0 
 
278 stents 
 
(58-95) 
 
UR and 
LUTS 
 
BPH 
 
Unclear 
Eichenauer 
1998 
Germany Journal 
Article 
9 86 78.9 (64-93) UR (n=58) 
LUTS (n=28) 
BPH (n=68)      
CaP (n=18) 
3-6 months 
Hamasaki 
2002 
Japan Journal 
Article 
3 17 82 (54-92) UR (n=15)  BPH or CaP (n=15) 
Neurogenic bladder 
(n=2) 
21.2 (6-25) months 
Itoh 1999 Japan Journal 
Article 
10 29 76.8 (61-85) UR (n=19) 
LUTS (n=10) 
BPH (n=22)      
CaP (n=7) 
Unclear 
Kawakami 
2003 
Japan Journal 
Article 
4 18 80 (65-92) UR (n=18) BPH 14 (3-18) months 
Kiyota 1994 Japan Conference 
Abstract 
3 17 N/S UR (n=15) 
LUTS (n=2) 
BPH 7 (4-9) months 
Kuriki 1995 Japan Journal 
Article 
8 32 74.9 (60-88) UR (n=18) 
LUTS (n=14) 
BPH 9.4 (1-25) months 
Matsuzaki 
2004 
Japan Journal 
Article 
11 15 77.2 (69-87) UR (n=8)   
LUTS (n=7) 
BPH 8 weeks 
Mellisourgos 
1999 
Greece Conference 
Abstract 
2 16 80.1 N/S BPH Unclear 
Mishra 2004 UK Conference 
Abstract 
6 31 79.6 (61-94) UR (n=18) 
LUTS (n=13) 
BPH Unclear 
Perry 2002 UK Journal 
Article 
10 211 80.2 (54-103) UR and 
LUTS 
BPH (n=194)    
CaP (n=17) 
7 years (max.) 
Poulsen 1993 Denmark Journal 
Article 
6 30 79 (61-87) UR (n=16) 
LUTS (n=14) 
BPH 3 (0.2-9) months 
Rathenbourg 
2001 
Denmark Conference 
Abstract 
3 28 80 (71-92) UR and 
LUTS 
BPH 30 (1-46) months 
Sumura 2002 Japan Journal 
Article 
8 25 80.7 UR (n=20) 
LUTS (n=5) 
BPH (n=18)      
CaP (n=7) 
 
Unclear 
UR - Urinary retention                          LUTS
 - Lower urinary tract symptoms 
BPH - Benign prostatic hyperplasia               
CaP - Carcinoma of prostate 
*All included studies were case series 
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Table 6.2: Timing and cause of Memokath stent failure 
 
Reference Number of 
patients (n) 
Mean / Median 
follow-up (range) 
Number and timing of stent failures 
   Immediate 
failure n (%)* 
 
Total failure  
n (%) in  
study period 
Details on cause and timing of the failure 
Booth 1997 (278$) Unclear - 88 (32) No details on cause or timing of failure. 
Eichenauer 1998 86 3-6 months 9 (10) 14 (16) 
 
Incorrect stent length/placement was 
reported as the cause of immediate failure. 
Cause of subsequent failure not specified. 
Hamasaki 2002 17 21.2                        
(6-25) months 
1 (6) 1 (6) Immediate failure: incorrect stent 
placement 
Itoh 1999 29 Unclear 0 10 (34) 
 
Migration (n=5); encrustation (n=3, at 6,10, 
and 12 months); dysuria (n=2). 
Kawakami 2003 18 14 (3-18) months 0 0  
Kiyota1994 17 7 (4-9) months - 7 (41) Obstructive symptoms (n=7) 
Kuriki 1995 32 9.4 (1-25) months 0 10 (31) Migration (n=6, at 2 months); encrustation 
(n=4, at 6,16,18,21 months). 14 further 
stents were removed as they were no 
longer required. 
Matsuzaki 2004 15 8 weeks 0 0  
Mellisourgos 1999 16 Unclear - 6 (38) Migration (n=6) 
Mishra 2004 31 Unclear 0 15 (48) Migration (n=5); retention (n=5); failure to 
improve symptoms (n=4); pain (n=1) 
Perry 2002 211  (217$) Unclear; up to 7 
years (max.).  
- 77 (36) 7 years follow-up reported for unclear 
number of patients, with no median or 
mean value reported. Reasons for removal 
included migration, worsening symptoms, 
encrustation, incontinence (n=44), 
repositioning for migration (n=33). 8 further 
stents were removed as they were no 
longer required. 
Poulsen 1993 30 3 (0.2-9) months 1 (3) 4 (13) Retention (n=2, at 2.5, 5 months); 
obstructive symptoms (n=1, at 3 months); 
incontinence (n=1, at 3 months). 
Immediate failure: incorrect placement. 
Rathenbourg 
2001 
 
28 30 (1-46) months 0 7 (25) Migration (n=3); incontinence (n=2); 
irritative symptoms (n=1); underactive 
detrusor (n=1). Median timing of failure at 
8 (1-31) months. 
Sumura 2002 25 Unclear 0 1 (4) Encrustation (n=1, at 12 months) 
Total n/N            
Total (%) 
839     (100)  11/311         
(4) 
240/839   
(29) 
 
*Immediate failure is given where explicitly indicated in the article                  $ (Number of stents used) 
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Chapter 7 
 
 
The UroLume stent for benign prostatic hyperplasia: a 
systematic review of the literature 
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7.1 Introduction 
 
The UroLume is the only prostatic stent which has been approved by the United 
States Food and Drug Administration (FDA) for the treatment of BPH.  It is 
manufactured from a metal alloy which is woven to form an expandable tubular 
mesh.  The UroLume stent can be inserted using local anaesthesia in the 
outpatient environment.  When placed in the prostatic urethra the stent exerts a 
radial force which holds the lumen patent and permits spontaneous voiding. 
 
The mesh structure of the UroLume stent allows epithelial incorporation, which 
confers theoretical advantages such as reduced rates of infection, stone 
formation and stent migration.  Conversely, epithelial incorporation may permit 
prostatic regrowth which can lead to a recurrence of LUTS and make stent 
removal difficult if it is required. 
 
The Memokath is an example of a different type of stent which does not allow 
epithelial in-growth, and is used predominantly in Europe.  A systematic review 
of the Memokath stent for BPH showed that it is safe and that the improvement 
in symptoms is comparable to that seen after TURP (see Chapter 6). 
 
In this Chapter we present the findings of a systematic literature review that 
assesses the effectiveness, durability and safety of the UroLume. 
 
 
7.2 Methods 
 
Inclusion and Exclusion Criteria.  We included studies of any design, and with at 
least ten patients, that evaluated the UroLume stent in men with BPH.  Case 
reports, editorials, and comments were excluded.  Review articles were excluded 
although their bibliographies were searched for additional relevant literature.  
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Studies of the UroLume for indications other than BPH, and animal studies were 
also excluded. 
 
Search Strategy.  Medline and Embase databases were searched between 1989 
(when the UroLume was first manufactured) and December 2005 using a 
comprehensive search strategy (see Appendix 4).  The bibliographies of all 
included papers along with those of six review articles [Donnell, 2003; Kapoor, 
2000; Lam, 2001; Oesterling, 1995; Ogiste, 2003; van Dijk, 2003] on stents were 
searched for additional literature.  The manufacturer of the UroLume stent 
(American Medical Systems, Minnetonka, USA) was contacted for further 
published and unpublished research and subsequently provided a bibliography.  
No language restrictions were imposed and non-English papers were translated. 
 
Outcomes.  Effectiveness was assessed in three ways.  First, by determining the 
proportion of catheter dependent men who were able to void spontaneously after 
insertion of the stent.  Second, by determining symptom score reduction.  Third, 
where possible, changes in uroflow parameters were assessed. 
 
Safety was determined by the incidence of complications.  These were divided 
into major complications which resulted in treatment failure (defined as the need 
for removal, replacement, or repositioning of the stent, or the need for another 
intervention to facilitate bladder drainage (for example, catheterisation, trans-
urethral resection)), and minor complications which did not. 
 
Data extraction and assessment of methodological quality.  All titles and 
abstracts were independently assessed for inclusion by two reviewers (J 
Armitage and P Cathcart).  Where there was insufficient detail the full paper was 
obtained. Where data was presented in abstract form only, the authors were 
contacted for further information. Data were independently abstracted from the 
literature by the same two reviewers and presented in structured tables for 
 102 
analysis.  Disagreements were resolved by discussion and consultation with a 
third reviewer (J van der Meulen). 
 
Methodological quality was appraised using criteria developed from published 
frameworks (see Appendix 3). [Downs, 1998; Khan, 2001; Lohr, 2004] 
 
Analysis.  Change in mean urological symptom score was presented graphically 
for each study.  Treatment failure rates were calculated immediately after the 
procedure and again at one year. 
 
 
7.3 Results 
 
Literature search. 548 articles were identified by the database search of which 
496 were excluded after reviewing their titles and abstracts (Figure 7.1).  Of the 
remaining 52 articles where the full paper was obtained, only 15 could be 
included in the final analysis. [Adam, 1990; Amón-Sesmero, 1998; Bajoria, 1995; 
Bellinzoni, 1993; Clemente, 1997; Comeri, 1995; Goepel, 1997; Guazzoni, 
1994a; Guazzoni, 1994b; Martorana, 1993; Masood, 2004; Milroy, 1993; 
Oesterling, 1994; Scarpone, 1992; Williams, 1993]  For example, 15 studies 
reported duplicated data, and 12 pertained to the exclusive use of different types 
of stent and were therefore excluded.  Two studies included less than ten 
patients and were excluded.  One paper was not available through academic 
institutions in the UK.  A further seven studies were identified by assessing the 
bibliographies of review articles, and three references were provided by the stent 
manufacturer.  Together these contributed a further five discrete studies which 
were suitable for inclusion. [Gabellon, 1994; Chapple, 1995; Epstein, 1994; 
Shapiro, 2004; Yip, 1997] 
 
Characteristics of included studies.  17 of the 20 studies were case series.  Two 
studies compared the performance of the UroLume stent with TURP. [Chapple, 
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1995; Epstein, 1994]  Although these trials were reported to be randomised they 
were only available as conference abstracts.  After contacting the authors there 
remained insufficient detail to allow an assessment of methodological quality.  
One study compared the UroLume stent with transrectal hyperthermia and 
transurethral thermotherapy. [Bellinzoni, 1993]  However, this study was not 
randomised and again insufficient information on patient demographics and poor 
methodology meant that meaningful comparisons were not possible.  Therefore, 
only men from these studies who received a UroLume stent were included in this 
review. 
 
Every effort was made to avoid the inclusion of duplicated data.  However, 
despite contacting the authors, replication remains a remote possibility. 
[Guazzoni, 1994a; Guazzoni, 1994b]  Where there were several reports from one 
group, [Masood, 2004; Oesterling, 1994] information was sought from all these 
sources, but only one study was cited in this review. 
 
Eight studies included more than 50 patients, and three, more than 100 in their 
analyses (Table 7.1).  The largest study included 135 patients. [Guazzoni, 
1994a] 
 
Quality assessment.  The methodological quality of the studies was generally 
poor.  For example, only 12 authors clearly outlined the study objectives.  Only 
five studies clearly accounted for patients lost to follow-up during the study 
period.  Statistical methods other than basic descriptive approaches were 
seldom employed and the funding source was made explicit in only two studies. 
 
On the other hand, most studies accurately described the recruitment period, 
defined patient characteristics well, and reported major adverse events 
comprehensively. 
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Patient demographics. (see Table 7.1)  A total of 990 patients were treated for 
bladder outlet obstruction with a UroLume stent.  The aetiology of obstruction 
was BPH in all but 9 patients who had carcinoma of the prostate.  About half of 
the patients were dependent on a urinary catheter for bladder drainage prior to 
UroLume insertion.  14 studies considered men who were mostly or exclusively 
at high operative risk, while 5 clearly stated that participants would normally have 
been considered suitable for surgery had they not been enrolled in the study. 
 
Effectiveness. 
Of the 990 patients included in the studies, 921 patients (93%) were able to void 
spontaneously following insertion of a UroLume stent (21 of these required a 
short period of suprapubic catheterisation).  One should note that approximately 
half of these men were treated for LUTS only and were therefore able to void 
spontaneously prior to receiving a stent.  Six studies included only patients who 
were dependent on a catheter prior to stent insertion. [Adam, 1990; Amón-
Sesmero, 1998; Comeri, 1995; Martorana, 1993; Shapiro, 2004; Yip, 1997]  148 
of the 176 men (84%) in these studies were able to void spontaneously after 
treatment with a UroLume. 
 
Urological symptom scores were reported in 13 studies. [Amón-Sesmero, 1998; 
Bajoria, 1995; Bellinzoni, 1993; Guazzoni, 1994a; Guazzoni, 1994b; Masood, 
2004; Milroy, 1993; Oesterling, 1994; Williams, 1993; Gabellon, 1994; Chapple, 
1995; Epstein, 1994]  Ten of these assessed symptoms before stent insertion in 
440 men although one reported an estimated score, [Amón-Sesmero, 1998] the 
validity of which is questionable.  All of these studies also reported reductions in 
symptom scores at some point in the first year after stent insertion, although the 
timing of assessment varied (Figure 7.2a).  Madsen-Iversen scores were 
reduced by 7.9 to 14.3 points and IPSS by 10 to 12.4 points.  These reductions 
in symptom score seemed stable in studies which reported longer follow-up 
although patient losses were often substantial.  Men who had been reliant on a 
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catheter prior to stent insertion reported symptom scores similar to those of men 
who had been treated for LUTS.  
 
Uroflow results were reported in 18 studies, 16 of which assessed mean peak 
urine flow rates.  11 studies assessed peak urine flow rates before and after 
stent insertion in men with LUTS (Figure 7.2b).  All of these studies reported 
increases in mean peak flow rates following stent insertion of between 4.2 and 
13.1ml/s.  Mean peak urine flow rates after UroLume insertion in men who had 
been catheter dependent varied from 8.8 to 20ml/s.  These improvements in flow 
rates appeared to become gradually less in studies which reported longer follow-
up. 
 
Durability. 
666 patients were evaluable at one year in 12 studies which provided detailed 
information on the timing of stent failure, and reported a mean follow-up of 12 
months or more. [Adam, 1990; Amón-Sesmero, 1998; Bajoria, 1995; Comeri, 
1995; Goepel, 1997; Guazzoni, 1994a; Guazzoni, 1994b; Masood, 2004; Milroy, 
1993; Oesterling, 1994; Gabellon, 1994]  104 stents (16%) failed during this 
period.  The commonest complication leading to stent failure (removal, 
replacement, or repositioning of the stent, or the need for further intervention to 
facilitate bladder drainage) in the first year was stent misplacement or migration 
(38 stents (37%)).  15 stents (14%) failed because of recurrence of obstructive or 
irritative voiding symptoms.  Furthermore 7 stents (7%) failed because of tissue 
hyperplasia, 5 (5%) due to stress incontinence, 4 (4%) as a result of chronic 
urinary retention, and 2 (2%) because of encrustation.  The reason for stent 
removal was not given in 33 cases (32%).  Accurate accounts of how these men 
were subsequently managed were not given. 
 
Three studies which included 232 patients allowed yearly stent failure rates to be 
calculated up to 2 years. [Bajoria, 1995; Masood, 2004; Oesterling, 1994]  A total 
of 33 stents failed in the first year (14%) and a further 16 stents failed in the 
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second year (8%).  Two of theses studies went on to report explantation rates 
beyond two years. [Masood, 2004; Oesterling, 1994]  The overall failure rate at 5 
years was 27% (50/188 stents) although a substantial number of patients had 
been lost to follow-up or had died with their stent in-situ. 
 
Safety 
Sixteen studies including 894 patients described minor complications explicitly 
although the timing of these events was not always clear. [Adam, 1990; Amón-
Sesmero, 1998; Bajoria, 1995; Bellinzoni, 1993; Clemente, 1997; Comeri, 1995; 
Goepel, 1997; Guazzoni, 1994a; Guazzoni, 1994b; Martorana, 1993; Masood, 
2004; Milroy, 1993; Oesterling, 1994; Scarpone, 1992; Williams, 1993; Yip, 1997]  
All of these studies reported the occurrence of perineal pain or irritative 
symptoms in some patients immediately following stent placement.  Furthermore, 
12 studies that included 591 men, found that most or all men were affected. 
[Adam, 1990; Amón-Sesmero, 1998; Clemente, 1997; Comeri, 1995; Goepel, 
1997; Guazzoni, 1994a; Martorana, 1993; Masood, 2004; Milroy, 1993; 
Scarpone, 1992; Williams, 1993; Yip, 1997]  These symptoms settled 
spontaneously in the majority of patients but some, with irritative symptoms, 
required treatment with anticholinergic drugs.  Out of all included patients 68 
men (7.3%) were reported to have urinary tract infections and 3 (0.3%) 
epididymo-orchitis within the follow-up periods.  However, the completeness of 
the reporting of infection is likely to be unreliable.  Other minor complications 
were rare. 
 
 
7.4 Discussion 
 
Our review demonstrates that most men (84%) who were catheter-dependent 
voided spontaneously after insertion of a UroLume stent.  The improvement in 
urinary symptoms was similar to that seen after TURP. [Flanigan, 1998]  
However, these results must be balanced against the one in six men who 
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required removal of the UroLume within 12 months of insertion and the 
occurrence of transient minor complications, such as pain and irritative voiding, 
immediately after insertion. 
 
Our review could only consider case series, most of which were of low quality.  
Most studies provided limited long-term data and gave inadequate accounts of 
the patients that were lost to follow-up.  This lack of long-term data limits the 
extent to which we can comment on durability beyond one year.  Having said 
this, we included three relatively large, prospective, multi-centre studies which 
scored reasonably well on methodological criteria. [Guazzoni, 1994a; Oesterling, 
1994; Williams, 1993]  Furthermore, most included studies were explicit in their 
reporting of immediate changes in urological symptoms associated with stent 
insertion and treatment failure within one year. 
 
It is worth noting that most patients in this review who received a UroLume stent 
had severe prostatic disease (approximately half were catheter dependent) and 
were at high risk of surgical complications.  Our findings are therefore applicable 
to patients who are older, less fit, and more likely to have detrusor failure and 
bacterial colonisation of the urinary tract, than men traditionally allocated to a 
surgical intervention.  None of the studies that were included in the systematic 
review undertook analyses according to any kind of stratification according to 
these risk factors. 
 
In 1997, the FDA approved the use of the UroLume for men older than 60 years 
and for men less than 60 at high operative risk.  This approval was based on the 
findings of only one study. [Oesterling, 1994]  Given the results of our systematic 
review, there seems to be no justification for altering the FDA’s decision.  This 
review also supports the recommendation of the AUA that stents should be 
‘considered only in high-risk patients’. [AUA Guideline on the Management of 
Benign Prostatic Hyperplasia: Diagnosis and Treatment Recommendations] 
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This systematic review, together with our previous systematic evaluation of the 
Memokath stent (Chapter 6), allows a comparison of the literature on the two 
principal stents available for the management of BPH.  The Memokath was 
designed to provide temporary relief of bladder symptoms, but is increasingly 
being used in Europe as a long-term treatment for BPH. [Madersbacher, 2006]  
The design of the UroLume allowing epithelial incorporation on the other hand 
was guided by the desire to prevent infection, encrustation and stent migration.  
The drawback of this design is that stent removal is more difficult and usually 
requires general anaesthesia. 
 
On the basis of the current evidence, both stents appear to be equally effective 
at relieving bladder outlet obstruction due to BPH.  The quality of the evidence 
on durability is better for the UroLume, so that treatment failure rates can be 
derived at one year for the UroLume but not for the Memokath. 
 
No advice can currently be offered to men in relation to durability of prostatic 
stents beyond one year for the reasons described above.  Future studies, on the 
UroLume or any other stent need to be designed in a way that long-term 
outcomes can be assessed.  Perhaps the optimal way to do this would be via a 
registry as happens with other implantable materials. 
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7.5 Tables and figures 
 
Figure 7.1: Summary of UroLume study selection process 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.1: Included UroLume studies and patient demographics 
Reference Country Type of 
publication 
Quality score 
(max 18) 
Participant characteristics  
    Number of 
participants 
Mean/Median age 
(range) 
Comorbidity Stent indication Pathology Mean/Median follow-up 
(range) 
Adam 1990 UK Journal article 4 21 75 (65-90) High risk AUR=18 CUR=3 BPH=19 CaP=2 12-16 months 
Amon-Sesmero 1998 Spain Journal article 10 78 79.6 (62-93) High risk Indwelling catheter=48 
AUR=26 Change stent=4 
BPH 15.3 (3-38) months 
Bajoria 1995 UK Journal article 7 47 67.7 (50-80) Fit for surgery AUR=10 LUTS=37 BPH 2 years max 
Bellinzoni 1993 Italy Journal article 11 30 >70 High risk LUTS BPH 1 year 
Chapple 1995 UK Conference 
abstract 
5 34 73 (65-90) Fit for surgery LUTS BPH 3 months 
Clemente 1997 Spain Journal article 10 19 79.8 (72-93) High risk AUR=17 LUTS=2 BPH 8.2 (1-18) months 
Comeri 1995 Italy Journal article 11 34 74.5 (68-84) High risk AUR/CUR BPH 14 (9-24) months 
Epstein 1994 US Conference 
abstract 
3 32 69.4 Fit for surgery LUTS BPH 6-24 months 
Gabellon 1994 Switzerland Conference 
abstract 
6 20 82.5 (70-93) High risk Indwelling catheter=17 
LUTS=3 
BPH 1 year 
Goepel 1997 Germany Journal article 8 37 79.4 (69-91) High risk AUR/CUR=15 LUTS=22 BPH 38.5 months 
Guazzoni 1994a Italy Journal article 10 100 75.2 (62-93) Most high risk AUR=61 LUTS=39 BPH 2 years max 
Guazzoni 1994b Italy Journal article 12 135 70.5 (50-85) Fit for surgery AUR=44 LUTS=91 BPH 18 months max 
Martorana 1993 Italy Journal article 6 21 77 (65-84) High risk AUR BPH Unclear 
Masood 2004 ⁮  UK Journal article 13 70 67 (40-89) Fit for surgery LUTS BPH 12 years max 
Milroy 1993 UK Journal article 8 54 75.7 (49-95) Most high risk AUR=34 CUR=12 LUTS=8 BPH=48 CaP=6 2 years max 
Oesterling 1994 ⁯ US Journal article 11 126 70 Not reported AUR/CUR=31 LUTS=95 BPH 2 years max 
Scarpone 1992 Italy Journal article 6 14 78 (68-95) High risk Unclear BPH=13 CaP=1 1 year 
Shapiro 2004 US Conference 
abstract 
4 10 86 High risk Indwelling catheter Unclear 6 months - 3 years 
Williams 1993 UK Journal article 7 96 (52-95) Most high risk AUR=73 CUR=11 LUTS=12 BPH 3 years max 
Yip 1998 China Journal article 7 12 80 (72-92) High risk AUR BPH 7 (2-18) months 
AUR - Acute urinary retention     LUTS - Lower urinary tract symptoms     CUR - chronic urinary retention     BPH - Benign prostatic hyperplasia     CaP - Carcinoma of prostate 
⁮ - Schneider and Anjum report earlier follow-up of these patients. ⁯ - Reports by Defalco, Shah, Marinkovic and Corujo as part of the North American UroLume study group contributed further information to this study. 
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Figure 7.2a: Change in urological symptom score associated with UroLume stent insertion 
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Figure 7.2b: Change in mean peak urine flow rates (Qmax) after UroLume stent insertion 
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8.1     Summary of thesis 
 
Section one 
Section one provided an introduction to and a general overview of this thesis.  In 
Chapter 1 the objectives of the thesis were introduced, together with a 
description of how this programme of work commenced.  The overall aim of this 
thesis was to investigate how the management of men with AUR could be 
improved.  AUR was identified as a common and severe complication of BPH 
and interrogation of the HES database was proposed as a means of 
investigating mortality in men who experience an episode of retention.  A lack of 
good quality evidence on the effectiveness, durability and safety of some 
minimally invasive alternatives to TURP was identified and systematic literature 
review was chosen as an appropriate next step in their evaluation. 
 
Section two 
Section two focused on the epidemiology of AUR.  Chapter 2 summarised the 
epidemiology and initial treatment of AUR particularly for the benefit of non-
urological readers of this thesis.  In recent years, a number of risk factors for 
AUR have been identified including age, prostate size and the severity of LUTS.  
Also, the introduction of medical therapy for LUTS attributable to BPH appears to 
have had a considerable effect on the incidence of AUR, its management, and 
the subsequent requirement for prostate surgery. 
 
Chapter 3 went on to investigate, for the first time, mortality rates after AUR 
using data from the HES database.  Mortality after a first episode of AUR in men 
admitted to hospital was found to be very high.  Overall, one in seven men with 
spontaneous AUR and one in four with precipitated AUR died within one year.  
Mortality rates increased strongly with age and the presence of comorbidity.  
Consequently, about half of the men aged over 85 years with at least one 
comorbid condition died within a year of their first episode of AUR.  Although 
mortality in men younger than 55 years without comorbidity was not as high, it 
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was still at least four times higher than that observed in men of similar age in the 
general population.  The high mortality that was observed suggests that these 
patients might benefit from early multi-disciplinary care to identify and treat 
comorbid disease. 
 
The importance of comorbidity on the outcome of AUR together with recognition 
of the need for accurate case-mix adjustment when assessing and comparing 
healthcare outcomes prompted the development of an improved and updated 
version of the Charlson Score to identify comorbidity in administrative data.  
Chapter 4 described a consensus meeting of surgical and epidemiological 
experts that took place at the Royal College of Surgeons of England.  The 
resulting RCS Charlson Score accounted for changes in the prognosis of some 
comorbid diseases since the Charlson Score was first developed 20 years ago.  
Furthermore, it was simplified to improve its accessibility and enhance its 
international transferability while taking into consideration the inherent limitations 
of routinely collected administrative data. 
 
The RCS Charlson Score was subsequently validated in patients undergoing a 
range of common surgical procedures (abdominal aortic aneurysm repair, aortic 
valve replacement, total hip replacement and TURP) using HES data.  The 
presence of at least one comorbid condition according to the RCS Charlson 
Score was associated with risk factors for comorbidity (for example, age, male 
sex and emergency admission) and with a poorer prognosis (for example, 
increased length of hospital stay, increased use of augmented care, and 
increased mortality).  Furthermore, prognostic models that included the presence 
of comorbidity according to the RCS Charlson Score performed better at 
predicting mortality than models that relied on administrative variables alone. 
 
Section three 
This section considered treatment alternatives to TURP for men with AUR in 
whom a conservative management approach fails.  These treatments are 
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generally considered to be less effective and less durable than TURP but on the 
other hand safer and associated with less morbidity.  Some may be carried out 
under local anaesthesia in the outpatient department and are therefore often 
referred to as minimally invasive treatments.  Chapter 5 introduced the minimally 
invasive treatment alternatives to TURP that are currently under evaluation 
within the context of clinical practice.  Microwave thermotherapy (TUMT) and 
transurethral needle ablation of the prostate (TUNA) use microwaves and 
radiowaves respectively to heat and ablate the occlusive prostate.  Lasers can 
be used in a similar manner to ablate or at higher power settings to resect 
prostatic tissue (for example, Holmium laser resection (HoLRP) or enucleation 
(HoLEP) of the prostate).  Each of these minimally invasive treatments has 
recently been evaluated by systematic review.  Both TUMT and TUNA were 
found to be less effective than TURP at reducing symptoms and increasing 
urinary flow rates but were associated with fewer adverse events. [Boyle, 2004; 
Hoffman, 2007]  Some of the laser prostate treatments, for example HoLEP, 
were shown to offer comparable effectiveness to TURP [Tan, 2007] although the 
extent to which these procedures can be considered truly minimally invasive is 
questionable. 
 
Inserting a prostatic stent to relieve bladder outlet obstruction in patients with 
AUR is an attractive concept as an alternative to surgery.  Although the 
technology has existed for more than 25 years, prostatic stents have not found 
wide acceptance within the urological community.  A perceived high complication 
rate has restricted their use to frail and elderly patients in whom surgery is 
deemed too dangerous.  However, unlike some of the other minimally invasive 
treatment alternatives to TURP, the effectiveness, durability and safety of 
prostatic stents had not been adequately evaluated. 
 
Chapters 6 and 7 presented systematic literature reviews of the Memokath and 
UroLume prostatic stents, those that are most commonly used in clinical practice 
today.  These systematic reviews found that insertion of either stent type was 
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associated with a reduction in urinary symptoms comparable to that seen after 
TURP.  Most men (84%) who were catheter-dependent voided spontaneously 
after insertion of a UroLume stent although one in six men required the stent to 
be removed within one year because of complications.  Unreliable, inconsistent 
and limited follow-up meant that conclusions on durability beyond one year could 
not be made for either stent type.  Therefore, the reviews support 
recommendations that the Memokath and UroLume stents should be considered 
only as treatments for elderly men and those at high operative risk.  They 
highlighted the need for further studies with extended follow-up to determine the 
durability of the stents. 
 
This thesis has provided important information on the long-term prognosis of 
men with AUR.  It has also considered the role of minimally invasive treatment 
alternatives to TURP and provided a systematic evaluation of prostatic stents.  
These findings have significant implications for the management of men with 
AUR and these are considered in the discussion below. 
 
 
8.2     Methodological challenges 
 
8.2.1 Hospital Episode Statistics database 
The Hospital Episode Statistics database is a unique data source because it 
provides information on all NHS hospital admissions in England.  For these data 
to be used reliably in healthcare research they must be complete and accurate.  
A number of processes are in place to ensure good data quality.  For example, a 
record submitted to HES will only be verified if it contains details of an 
appropriate hospital provider, details of the type of admission and if it also 
contains a date for the end of that episode which falls within the appropriate HES 
year.  A process called ‘autocleaning’ ensures that data fields make sense both 
in isolation and also with reference to other fields.  Incorrect fields are overwritten 
if the correct value can be derived from other data fields, for example, duration of 
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episode can be calculated if admission and discharge dates are known.  In a 
further step called ‘validation’ all records are tested against a set of rules to 
identify problems that persist after autocleaning.  A report on the quality of the 
submission is then generated.  The performance of data providers may be 
assessed using this information and this process helps to maintain and improve 
data quality. 
 
A number of studies have investigated the accuracy of HES data.  A recent 
systematic review of studies that compared routine discharge statistics with 
medical casenotes found the median coding accuracy of more than 90% for 
diagnostic codes although this fell to 70% when procedural codes were 
considered. [Campbell, 2001]  There is also evidence that the accuracy of coding 
has improved considerably over the last decade. [Hansell, 2001]  A study that 
compared the accuracy of HES coding for varicose vein surgery to local audit 
data found that coding accuracy in 1989 was 45% compared to 98% in 1995. 
[Galland, 2000] 
 
Clearly HES data must be complete and accurate but for any comparisons of 
healthcare performance to be reliable, robust interpretation of these data is also 
essential.  This thesis has demonstrated the importance of precisely defining the 
study population.  For example, in Chapter 3 we investigated the mortality of 
men with a first episode of AUR that had occurred as a result of BPH.  Identifying 
these patients in HES required a step-wise process.  First, the records of all 
female patients were excluded.  Second, patients who had experienced AUR 
were identified using a single ICD-10 code (R33) that is unambiguous and 
therefore likely to be recorded accurately.  Third, all of the records of patients 
who had prostate cancer or neurological disease were deleted.  Patients with 
AUR in a record from the first year of the study period could not be included as 
these men may have had an earlier episode of AUR for whom this admission 
represented a recurrent episode rather than the first episode.  Further 
categorisation according to whether AUR was spontaneous or precipitated was 
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important and required additional careful data manipulation.  Similar rigorous 
consideration was given to each of the study populations defined in Chapter 4. 
 
Researchers who use administrative data such as HES in health services 
research must also be alert to data quality issues that arise.  In Chapter 3, for 
example, 2.4% of men who were reported as having died after AUR were found 
to have a record of a subsequent hospital admission.  For these contradictory 
results, the information on death was considered to be erroneous and these men 
were therefore analysed as being alive until the end of the study period.  
Therefore, this thesis emphasises the importance of judicious interpretation and 
appropriate responses to any data inaccuracies within HES. 
 
Ensuring adequate adjustment for case-mix is an essential component of any 
study that reports surgical activities or outcomes.  Case-mix adjustment should 
include an estimate of the severity of the primary disease as well as determining 
the presence and severity of comorbid diseases (coexisting but unrelated 
conditions that may affect a patient’s prognosis in addition to the primary 
disease).  It presents a particular methodological challenge when administrative 
data are used because these sources frequently lack detailed clinical 
information.   
 
A number of instruments have been used to identify comorbid disease in 
administrative data and of these, adaptations of the Charlson Score have been 
the most widely used and validated.  Previous work has demonstrated that ICD-
10 adaptations of the Charlson Score can be used to identify comorbid disease 
to an extent necessary to control for differences in case-mix between different 
patient populations. [Nuttall, 2006]  In Chapter 4 of this thesis we developed the 
RCS Charlson Score that is a simple, valid and internationally applicable method 
for comorbidity adjustment in administrative data that builds on this earlier work.  
Furthermore, Chapter 4 identified important general principles for comorbidity 
adjustment in administrative data that may be used as a basis for further 
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research in this area.  The utility of the RCS Charlson Score must now be 
demonstrated in further studies that include different patient groups. 
 
8.2.2 Systematic reviews of observational studies 
The validity and applicability of a systematic review depends on the quality of the 
primary studies that are included.  A systematic review that includes only 
observational studies is subject to confounding, and selection and information 
biases that may lead to uncertainty in the estimates of treatment effect.  
Reviewers should be aware of these risks and users of systematic reviews that 
include non-randomised data should be careful not to over interpret their 
findings. [Deeks, 2003]  An attempt must therefore be made to minimise these 
potential biases by including a methodological quality assessment of the studies 
that are included in a systematic review. 
 
The systematic reviews of prostatic stents presented in Chapters 6 and 7 
evaluated the methodological quality of all potentially relevant studies using an 
18 point checklist developed from published frameworks specifically for the 
appraisal of non-randomised studies (see Appendix 3). [Downs, 1998; Khan, 
2001; Lohr, 2004]  These criteria hardly differed from those proposed in the 
STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) statement that has since been published. [von Elm, 2007]  For 
example, both checklists highlighted the importance of stating the specific 
objectives of the study and clearly defining the outcomes of interest.  They also 
identified the need for detailed reporting of the characteristics of included 
patients, how they were selected and an accurate account of those lost to follow-
up.  A discussion of the study limitations as well as the generalisability of the 
findings should also be included.  A checklist such as the one developed in this 
thesis, or that which was published in the STROBE statement, provides 
important information on the quality of observational studies.  The 
methodological assessment of the quality of observational studies included in a 
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systematic review helps to determine the validity and justifiability of its 
conclusions. 
 
If the inherent limitations of non-randomised studies are recognised, their 
inclusion in a systematic review may contribute substantially to the evidence 
base for a particular intervention especially where randomised controlled trial 
evidence is lacking or indeed absent.  Moreover, a recent review of empirical 
studies suggests that meta-analyses based on observational studies generally 
produce estimates of treatment effect similar to those from meta-analyses based 
on randomised controlled trials. [Shrier, 2007]   
 
 
8.3     Clinical implications 
 
8.3.1 Identifying and treating comorbidity in men with AUR 
The high mortality of men with AUR reinforces the importance to the clinician of 
adopting a multi-disciplinary approach when assessing and managing men with 
AUR.  We found that men with AUR who have comorbidity are at the greatest 
risk of death.  Therefore, men who experience AUR should undergo a 
comprehensive assessment for the presence of comorbid disease and where it is 
identified it should be treated appropriately. 
 
Our observation that about half of the deaths after AUR occur within the first 90 
days suggests that assessment for comorbidity must occur promptly.  Taking the 
need to be timely one step further, one could claim that to be most effective 
screening for other morbidities should start in men presenting with LUTS 
attributable to BPH before these patients have experienced AUR. 
 
We found that about 30% of patients with AUR had co-existing cardiovascular 
disease, 25% had diabetes and 25% chronic pulmonary disease.  The relatively 
high prevalence of cardiovascular disease and diabetes is consistent with the 
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findings of recent aetiological studies linking hypertension and metabolic 
syndrome with the progression of BPH. [Michel, 2004; Ozden, 2007]  
Furthermore, the high prevalence of these conditions implies that some men 
presenting with AUR will have undiagnosed comorbidity.  Clinicians should 
specifically enquire about the presence of these diseases and their risk factors, 
and liase with the primary care physician to address their management.  Perhaps 
all men with AUR should have their BMI (body-mass index) calculated, and have 
their blood glucose and blood pressure checked. 
 
However, the extent to which mortality after AUR can be reduced will depend on 
the nature and severity of the comorbid diseases involved and the effectiveness 
of the available treatments.  For example, some patients will have comorbidity 
that is already optimally treated and for whom little further can be done. 
 
Perhaps the urologist should become an advocate for men’s health in general. 
[Kirby, 2005]  Men are often ignorant of the diseases at which they are most at 
risk and there is a general reluctance of men to seek medical advice.  One of the 
first contacts with the medical profession may be with a urologist because of 
urinary symptoms or erectile dysfunction.  This consultation provides a unique 
opportunity for the urologist to enquire about associated health issues, arrange 
investigation and institute appropriate management.  For example, erectile 
dysfunction shares the same risk factors as ischaemic heart disease and 
cerebrovascular disease. [Thompson, 2005]  Similarly, patients presenting to the 
urologist with LUTS who are found to have diabetes or hypertension may be 
commenced on treatment and smokers with urothelial carcinoma may be 
introduced to cessation programmes.  The findings of this thesis support a 
holistic approach and suggest that patients presenting with LUTS or AUR 
undergo a thorough evaluation for the presence of comorbid disease. 
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8.3.2 Treatment options for men with AUR 
The management of AUR has changed considerably in recent years.  For 
example, the introduction of medical therapies for LUTS appears to have 
changed the natural history of BPH, with alpha-receptor blockers delaying 
disease progression and 5-alpha reductase inhibitors actually reducing the long-
term risk of developing AUR. [McConnell, 2003]  Moreover, whilst AUR was once 
considered an absolute indication for TURP, now most men with urinary 
retention will have at least one trial of voiding prior to considering surgery.  Fears 
that this approach will merely delay the inevitable need for surgery appear to be 
unfounded in light of recent studies that have shown that the shift away from the 
surgical treatment of BPH has not resulted in an increase in AUR. [Cathcart, 
2006] 
 
For men with AUR who do not pass urine following a TWOC, have refractory 
LUTS, or experience complications of BPH such as a recurrent episode of AUR, 
there are now a number of minimally invasive treatment alternatives to TURP.  
This thesis has considered some of these minimally invasive treatments (see 
Chapter 5) and has evaluated the effectiveness, safety and durability of prostatic 
stents by systematic literature review (see Chapters 6 and 7).  Minimally invasive 
treatments tend to be less effective and less durable but are generally 
associated with a lower risk of morbidity.  These treatment-related factors 
constitute an important part of the discussion when counselling a man with AUR 
about his management options. 
 
Many patient-related factors also influence the type of treatment that is offered to 
a man with AUR.  For example, the size of the prostate, the retention volume and 
hence possible bladder dysfunction, the suspicion of malignancy, the use of 
anticoagulant medication, and the patient’s expectations and attitudes towards 
the various treatments must all be considered.  Also of significance, especially in 
light of the findings of the study presented in Chapter 3 of this thesis, are the 
patient’s age and the presence of comorbid disease. 
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Older men with comorbid disease who experience AUR may be more 
appropriately offered a treatment with lower morbidity, accepting that it may be 
less effective and less durable than other options.  For example, prostatic stents 
may represent a useful alternative to a long-term catheter in men with AUR who 
are deemed unfit for surgical procedures such as TURP. 
 
Conversely, the morbidity associated with a procedure may be an important 
factor for young men with AUR who may wish to avoid, or at least defer, some of 
the risks associated with surgery while accepting a potentially less effective and 
less durable treatment.  For example, laser ablation procedures may be 
associated with a lower risk of retrograde ejaculation than laser enucleation 
procedures or TURP. 
 
 
8.4     Research implications 
 
8.4.1 Extending the role of administrative databases in health services 
research 
Administrative databases such as HES were not designed to answer specific 
research questions.  However, because they contain patient-level data including 
identity, treatment and some health state or outcome data they are increasingly 
being used for healthcare research purposes.  For example, in the UK HES data 
have been used to study the epidemiology of disease, [Cathcart, 2005; Roche, 
2005] evaluate variations in healthcare outcomes [Nuttall, 2004; Aylin 2007] and 
in Chapter 3 of this thesis HES data were used to investigate mortality after 
AUR. 
 
Studies that use administrative data to evaluate healthcare outcomes require 
adequate case-mix adjustment and the RCS Charlson Score presented in this 
thesis and discussed earlier in this chapter is an important component.  
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However, there are many other important factors in case-mix adjustment that are 
not readily derived from administrative datasets. 
 
For example, the severity of the primary disease is another key determinant of 
outcome.  This information is often not directly available from HES data although 
occasionally it may be inferred by association.  For example, in patients 
undergoing aortic valve replacement the presence of congestive cardiac failure 
implies more severe disease (see Chapter 4). 
 
Therefore, the utility of administrative data may be enhanced through linkage 
with other databases and registries that provide information on disease severity.  
For example, cancer registries often provide information on the severity of the 
disease by way of cancer staging (how advanced the cancer is).  A US study that 
investigated mortality after radical prostatectomy for prostate cancer used routine 
data from Medicare linked to cancer staging data from the Surveillance, 
Epidemiology, and End Results (SEER) registry. [Begg, 2002]  Linkage of HES 
data with the General Practice Research Database could provide important 
additional information on comorbidity that would help to define its effect on 
mortality after AUR.  Conversely, the value of cancer registries may be increased 
through linkage with administrative data sources.  A recent UK study found the 
reporting of ethnicity data in HES far better than in a regional cancer registry and 
suggested data linkage as a means of overcoming deficiencies in the registry 
data. [Jack, 2006] 
 
Linkage of administrative databases with clinical databases and registries also 
provides important additional information on healthcare outcomes.  For example, 
the linkage of the central cardiac audit database with mortality data from the 
Office for National Statistics database allowed indefinite tracking of mortality of 
cardiac patients. [Keogh, 2005]  More recently HES data have been linked to the 
ONS mortality database making studies such as that presented in Chapter 3 of 
this thesis that assessed mortality rates after AUR possible.  HES linked ONS 
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mortality data now include not only date of death but also cause of death which 
could help to explain the reasons for the high mortality after AUR.  Detailed 
information on the incidence of complications as well as important outcomes 
such as health-related quality of life might also be obtained through linkage with 
clinical databases. 
 
Research building on administrative databases, such as HES, enriched through 
linkage with additional clinical data may be used to further define the importance 
of comorbidity in patients with AUR and investigate the extent to which its 
treatment will reduce mortality.  First, administrative databases can provide near 
complete follow-up in terms of further treatment as well as death.  Clinical data, 
perhaps collected prospectively in a subgroup of patients and linked to the 
administrative data at individual patient level, will allow a further exploration of 
the impact of comorbidity according to its nature and severity.  It can be 
envisaged that the results of this step will inform the development of treatment 
strategies.  Second, these strategies can then be evaluated using research 
designs that build on combining administrative data with data derived from 
clinical trials. 
 
The linkage of databases therefore provides a powerful way of extending their 
utility and also permits cross validation of data.  For example, The Clinical 
Effectiveness Unit of The Royal College of Surgeons of England has linked 
prospective data from the National Joint Registry with HES data at hospital level.  
[National Joint Registry for England and Wales. 4th Annual Report]  This study 
allowed the determinants of outcomes such as mortality and length of stay after 
hip and knee replacement to be investigated.  The generation of electronic 
patient records may in time allow data from clinical and administrative databases 
to function as one, with each acting as a source of validation and corroboration 
of the other. [Connecting for health, NHS Care Records Service. 
http://www.connectingforhealth.nhs.uk/systemsandservices/nhscrs] 
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In the UK there have been recent failures of the medical profession to identify 
poor performance of both individual medical practitioners [The Shipman Inquiry - 
Final Report, 2005] and hospital providers. [Learning From Bristol - Bristol Royal 
Infirmary Inquiry, 2001]  Therefore, there is an increasing requirement for 
openness, public accountability and the transparent provision of high quality 
healthcare.  As part of this, the Department of Health believes that the 
publication of survival rates after surgery will provide an incentive to the medical 
profession to maintain and improve standards and at the same time reassure the 
public that these efforts are being made.  This is a view that is supported by The 
Royal College of Surgeons of England which believes that the publication of 
outcomes as a combination of patient reported outcomes measures, routinely 
collected administrative data and the results of clinical audits will lead to 
improving the quality and standards across surgery. [Royal College of Surgeons 
response to Lord Darzi's NHS Next Stage Review, 2008] 
 
Since 2005 mortality data that has been voluntarily supplied by cardiac units for 
all cardiac surgeons in the UK have been made publicly available.  More recently 
in 2008 the Department of Health published mortality rates for abdominal aortic 
aneurysm repairs (elective and emergency), elective hip replacements and knee 
replacements, information that was derived from the HES database. [NHS 
Choices, 2008] 
 
Publication of these data is still controversial.  For example, it has been 
suggested that it may lead surgeons to refuse difficult cases or may result in 
surgeons and healthcare providers being penalised unfairly if data are 
inaccurate.  It is therefore imperative that these data are reliable and measures 
taken to provide accurate adjustment for differences in case-mix.  This thesis has 
shown that HES data can be reliably used to answer important healthcare 
questions and through the development of the RCS Charlson Score will hopefully 
extend the utility of this valuable data source. 
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8.4.2 Appraisal of minimally invasive prostate treatments 
Recently, traditional surgical techniques have been challenged by numerous 
minimally invasive treatment alternatives to TURP.  Some of these have been 
introduced into clinical practice and continue to undergo evaluation in this 
context, while others have been abandoned because of concerns over their 
effectiveness, durability and safety.  Unfortunately, the rapidity with which many 
of these technologies have been developed has often precluded their adequate 
assessment, as demonstrated in Chapters 6 and 7 with prostatic stents.  
However, rigorous evaluation of these interventions is essential so that clinicians 
can provide patients with accurate information and ensure that the most 
appropriate treatments are offered to them.  Some of the challenges facing 
researchers when evaluating new minimally invasive prostate treatments are 
now considered. 
 
Limitations of randomised controlled trials 
Randomised controlled trials (RCTs) have been considered by many to be the 
only reliable means of evaluating healthcare interventions.  This study design 
ensures that the comparison groups differ only in their exposure to the 
intervention and may therefore provide the best estimate of treatment effect.  
However, when evaluating surgical procedures, such as minimally invasive 
prostate treatments, RCTs are sometimes unnecessary or unfeasible and in 
these situations observational studies may be more appropriate.  Furthermore, 
there is increasing recognition that the two approaches - RCTs and observational 
studies - have complementary roles in the assessment of healthcare 
interventions.  
 
An important limitation of RCTs is that their external validity (the generalisability 
of their findings) may be limited. [Black, 1996; McKee, 1999]  For example, RCTs 
are frequently conducted by experienced clinicians under optimal conditions and 
do not therefore reflect real life practice.  Furthermore, stringent inclusion and 
exclusion criteria may result in a highly selected study group that is not 
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representative of the population for whom the intervention is ultimately intended.  
Therefore, the effectiveness of an intervention in everyday clinical practice may 
be better assessed by population-based observational studies.  Such studies will 
be representative of all patients but control of confounding will be limited to those 
factors that are recognised as important and are measured.  The issue of 
generalisability is particularly pertinent in surgery where outcomes are very 
dependent on the experience and expertise of the surgeon and of the unit where 
the procedure is carried out. 
 
For RCTs to be ethical there must be sufficient doubt about the relative merits of 
the different treatment options.  Where clinicians do not accept that there is 
uncertainty about the effectiveness of different interventions RCTs are 
inappropriate.  This is often the case for minimally invasive prostate treatments 
that are not designed to provide comparable effectiveness to TURP.  For 
example, we showed in Chapters 6 and 7 that prostatic stents are effective at 
restoring spontaneous voiding in most men with AUR but that their use should 
probably be restricted to a subgroup of patients who are not fit for surgery.  
Therefore, an RCT comparing prostatic stents to TURP would not be 
appropriate. 
 
The role of data registries 
Data registries can be used to evaluate healthcare technologies that are already 
in clinical use.  Registries only record data that are derived from the 
administration of routine clinical care.  Therefore, these patients should be 
representative of those for whom the intervention is intended in ‘real-life’ 
practice.  The ethical concerns facing clinicians when enrolling patients in clinical 
registries are also fewer because patients receive only the treatment that they 
would normally be given.  Clinical registries are relatively cheap and may 
therefore be maintained for many years thus providing important information on 
rare and late complications and on the durability of treatments. 
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There are many examples of clinical registries in the UK.  For example, the 
National Joint Registry (NJR) was established in 2003 with the aim of collecting 
data on all joint replacements carried out in England and Wales. [National Joint 
Registry]  The NJR appears to fulfill its specific objectives that are to improve 
clinical care through identifying best practice in orthopaedic units and to provide 
information on the performance of the various implants. 
 
The introduction of a clinical registry may therefore be the most appropriate next 
step in the evaluation of prostatic stents and other minimally invasive prostate 
treatments.  The systematic reviews of prostatic stents presented in Chapters 6 
and 7 identified a lack of long-term data on the durability of prostatic stents.  The 
challenge of maintaining a clinical trial for a prolonged period to collect 
information on durability is compounded by the age and frailty of the patients 
who are typically treated with prostatic stents.  A stent registry would provide 
good evidence of durability as well as additional information on safety and 
effectiveness. 
 
Importance of evaluating short-term morbidity versus long-term benefit 
When considering the morbidity associated with minimally invasive prostate 
treatments, factors such as the inconvenience of the procedure, post-operative 
pain and discomfort, and the time to recovery of functional status are also 
important.  However, it can be difficult to accurately assess this short-term 
morbidity.  For example, generic surgical complications such as fever, urinary 
tract infection, wound infection and bleeding are often poorly defined.  Moreover, 
a recent systematic review found inconsistency in the quality of reporting of post-
operative adverse events, limiting accurate comparison of rates over time and 
between institutions. [Bruce, 2001]  A reliable and valid approach to assess 
short-term morbidity would be of great value when assessing minimally invasive 
prostate treatments as this information may influence a patient’s decision when 
selecting treatment. 
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The Postoperative Morbidity Survey (POMS) is the only published prospective 
method that attempts to capture the short-term morbidity associated with major 
surgery. [Bennett-Guerrero, 2001]  This instrument aims to provide a simple 
means of identifying short-term morbidity of a type and severity that could delay 
discharge from hospital.  It contains 18 items that address nine domains of post-
operative morbidity and is starting to be used in both outcomes [Bennett-
Guerrero, 2001] and effectiveness research. [Wakeling, 2005]  A recent study 
that assessed short-term morbidity in patients undergoing elective major 
orthopaedic, gastrointestinal and urological surgery in a UK teaching hospital 
found the POMS to be valid and reliable. [Grocott, 2007] 
 
Harder still are estimations of the degree and duration of post-operative pain and 
of the impact of surgery on a patient’s functional status.  A number of generic 
and disease-specific instruments to measure health related quality of life have 
been developed.  These ‘patient reported outcome measures’ are an essential 
part of the evaluation of healthcare interventions and also allow the comparison 
of healthcare providers. [Browne, 2008]  Future studies that assess minimally 
invasive prostate treatments that may sacrifice some effectiveness for improved 
safety and quicker recovery, should attempt to quantify short-term morbidity and 
assess patient reported outcomes. 
 
 
8.5     Concluding remarks 
 
This thesis has demonstrated that the mortality of men with AUR is high and 
increases strongly with age and the presence of comorbid disease.  When 
assessing patients with AUR urologists are in a unique position where by actively 
seeking comorbidity and by instituting appropriate management they may help to 
reduce its associated mortality. 
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The important influence of comorbidity on mortality of men with AUR prompted 
the development of The RCS Charlson Score to improve comorbidity 
identification in HES.  The RCS Charlson Score uses an explicit coding 
philosophy that is simple to use, more accurate than existing instruments, 
reflects the current understanding of the prognostic impact of comorbidity and 
allows international comparisons.  It was developed on the basis of sound 
general principles for identifying comorbidity that should extend the role of 
administrative data such as HES in health services research.  Moreover, through 
linkage with clinical data sources it is hoped that HES data may be used to 
enhance our understanding of the epidemiology and optimal management of 
AUR.   
 
Given that many men with AUR are elderly, have significant comorbidity and 
therefore have a high risk of death, minimally invasive treatment alternatives to 
surgery for AUR were considered.  Systematic literature review defined the role 
of prostatic stents as an effective treatment option for frail and elderly men.  
Although only observational data were available a specifically developed 
checklist to assess methodological quality gave context to the review findings.  
This thesis has also highlighted the importance of reliable evaluation of new 
technologies such as minimally invasive treatment alternatives to TURP. 
 
The overall aim of this thesis was to investigate how to improve the management 
of men with AUR.  Its principle finding is that the management of AUR must 
focus not only on the prostate but also on the patient’s overall health status.  The 
urologist should adopt a holistic approach when assessing and treating a man 
with AUR to ensure the best possible outcome.  
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Appendix 2 
 
Memokath systematic literature review search strategy (Medline) 
 
 
Population terms 
 
1 exp. prostatic hyperplasia# 
2 exp. prostate# 
3 ((hypertroph$3 or hyperplas$3) near prostat$3) 
4 adenoma near prostat$3 
5 prostatism 
6 intraprostatic 
7 (bladder near (outflow or outlet) near obstruct$3) 
8 exp. bladder-neck-obstruction# 
9 LUTS 
10 lower adj urinary adj tract adj symptoms 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
 
Intervention terms 
 
12 exp. stents# 
13 stent$3 
14 memokath$ 
15 prosthes$ 
16 spiral 
17 12 or 13 or 14 or 15 or 16 
 
Combined terms 
 
18 11 and 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
Appendix 3 
 
Checklist for the assessment of methodological quality of observational 
studies 
 
 
 
Criterion 
 
 
Yes 
 
No 
 
Unclear 
 
N/A 
     
1. Is the aim/objective of the study clearly 
described? 
    
2. Are the main outcomes to be measured clearly 
described in the Introduction or Methods section? 
    
3. Are the inclusion/exclusion criteria explicit?     
4. Are the characteristics of the patients included in 
the study clearly described? 
    
5. Were the subjects asked to participate in the 
study representative of the entire population from 
which they were recruited? 
    
6. Did all individuals enter the study at a similar 
point in their disease progression? 
    
7. Was patient selection consecutive?     
8. Was data collection prospective?     
9. Was the recruitment period clearly defined?     
10. Does the study provide estimates of the random 
variability in the data for the main outcomes? 
    
11. Were the main outcome measures used accurate 
(valid and reliable)? 
    
12. Have all important adverse events that may be a 
consequence of the intervention been reported? 
    
13. Are the main findings of the study clearly 
described? 
    
14. Were the statistical methods used to assess the 
main outcomes appropriate? 
    
15. Do the analyses adjust for different lengths of 
follow-up of patients? 
    
16. Have the characteristics of patients lost to follow-
up been described and have these losses been 
taken into account? 
    
17. If comparisons of sub-series are being made was 
there sufficient description of the series and the 
distribution of prognostic factors? 
    
18. Was the funding source made explicit if 
applicable? 
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Appendix 4 
 
UroLume systematic literature review search strategy (Medline) 
 
 
Population terms 
 
1 exp. prostatic hyperplasia# 
2 exp. prostate# 
3 ((hypertroph$3 or hyperplas$3) near prostat$3) 
4 adenoma near prostat$3 
5 prostatism 
6 intraprostatic 
7 (bladder near (outflow or outlet) near obstruct$3) 
8 exp. bladder-neck-obstruction# 
9 LUTS 
10 lower adj urinary adj tract adj symptoms 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
 
Intervention terms 
 
12 exp. stents# 
13 stent$3 
14 urolume$ 
15 prosthes$ 
16 spiral 
17 12 or 13 or 14 or 15 or 16 
 
Combined terms 
 
18 11 and 17 
